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ABSTRACT OF THE DISSERTATION 
 
Chemical Syntheses and Cellular Replication Studies of DNA Alkyl Phosphotriester 
Lesions 
 
 
By 
 
 
Jiabin Wu 
 
Doctor of Philosophy, Graduate Program in Environmental Toxicology  
University of California, Riverside, December 2019 
Dr. Yinsheng Wang, Chairperson 
 
Exposure to endogenous and exogenous factors could give rise to DNA damage. 
DNA alkylation constitutes a major form of DNA damage, and alkyl phosphotriesters 
(alkyl-PTEs) are particularly important owing to their relatively high frequencies of 
occurrence and resistance to repair in mammalian cells. However, little is known about 
how alkyl-PTEs influence fidelity and efficiency of DNA replication in cells and how 
translesion synthesis (TLS) polymerases modulate the replicative bypass of these lesions.  
In Chapter 2. We synthesized and characterized oligodeoxynucleotides (ODNs) 
containing site-specifically inserted alkyl-PTEs (Me, Et, nPr and nBu) with different 
alkyl groups and diastereomeric configurations (Sp and Rp) and assessed how these 
lesions impact DNA replication in E. coli cells. Our results revealed that Sp-alkyl-PTEs 
viii 
 
could be efficiently bypassed, whereas their Rp counterparts exhibited moderate blockage 
effects on DNA replication. Additionally, Sp-Me-PTE was found to induce TT→GT and 
TT→GC mutations, which necessitated Ada proteins. 
In Chapter 3. We prepared Me- or nBu-PTE-containing ODNs in two diastereomeric 
forms with different flanking dinucleotides sequences (XT and TX, X=A, C, G) and 
examined how these lesions were recognized by DNA replication machinery in E. coli 
cells. We found that Sp-XT-Me-PTEs were efficiently bypassed with similar distributions 
in replication products (with approximately 85-90% AT and 5-10% TG at XT site). where 
Ada protein is essential for the generation of the mutagenic products. Additionally, Rp-
XT-Me-PTEs and both diastereomers of TX-Me-PTEs displayed error-free bypass with 
significant blockage effects. We also found that Ada binds strongly to Sp-Me-PTE at AT 
site, but not TA site. Our results suggest that the role of Ada may be beyond the repair of 
Sp-Me-PTE lesion and transcriptional modulation of genes involved in repairing alkylated 
DNA lesions. 
In Chapter 4, we analyzed the cytotoxic and mutagenic properties of 
pyridyloxobutyl (POB)-PTEs in E. coli cells. We demonstrated that POB-PTEs did not 
display strong impediments to DNA replication, and replicative bypass of POB-PTEs 
does not require TLS polymerases. In Addition, POB-PTEs were not mutagenic. 
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Together, the research described in this dissertation constitutes the first chemical 
syntheses of ODNs harboring stereochemically defined alkyl-PTE lesions, and provides a 
much better understanding about the biological consequences of alkyl-PTE lesions. 
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CHAPTER 1 
 
General Introduction 
 
 This chapter will cover the general background of the research projects discussed in 
this dissertation.    
DNA Alkylation 
DNA carries the genetic information, but it has limited chemical stability (1); hence 
the integrity of DNA is constantly challenged by endogenous and exogenous factors, which 
lead to different kinds of DNA damage, which may result in mutagenesis and ultimately 
carcinogenesis (1-3). 
DNA alkylation is a common type of DNA damage (4), and it also constitutes a major 
mechanism for many prescribed chemotherapeutic agents (2). According to Anatomical 
Therapeutic Chemical classification system code L01A, which is developed by World 
Health Organization Collaborating Centre for Drug Statistics Methodology, alkylating 
agents can be classified into 6 groups: nitrogen mustard analogues, alkyl sulfonates, 
ethylene imines, nitrosoureas, epoxides and other alkylating agents. Alkylating agents can 
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attack different nucleophiles on DNA to form various alkylation products, and depending 
on the positions of nucleophiles being attacked, alkylated DNA lesions can be divided into 
two groups: base alkylation and backbone alkylation. So far, base alkylation constitutes the 
major concern for DNA alkylation studies (5). However, backbone alkylation products, 
also known as alkylphosphotriester (alkyl-PTE), which is formed from alkylating agents 
attacking the non-carbon-bonded oxygen atoms on the phosphate backbone (6), came to 
our sight in recent years, and it constitutes the focus of this thesis. 
Formation of Alkylphosphotriester 
In 1948, it has been shown that mustard gas could react with phosphate backbone to 
form “secondary phosphoryl” adduct (7). Later, detailed studies indicated that many 
alkylating agents, such as N- methy-N-lnitrosourea (MNU), N-ethyl-N-nitrosourea 
(ENU), diazomethane and methyl methanesulfonate (MMS) could induce the formation 
of backbone alkylation products (8-10). Recent research also revealed that the methyl 
diazohydroxide, a bioactivation product of tobacco-specific nitrosamines, N-nitrosamine 
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and its metabolite 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), could also react with DNA to 
form backbone methylation product (11), establishing the relationship between the 
formation of alkyl-PTEs and tobacco smoking. Since each phosphodiester bond has two 
non-carbon-bonded oxygen atoms, and alkylating agents can attack either of them, every 
3 
 
type of alkyl-PTE is present in two diastereomeric configurations (Figure 1-1). The 
diastereomeric difference of alkyl-PTEs has biological significance, which would be 
illustrated in detail in this dissertation. 
 
 
Figure 1-1. The structure of phosphotriester, ‘X’ represents different alkyl groups.  
 
Chemically, alkyl-PTEs are labile under basic condition and stable under neutral and 
acidic conditions (8,12), and they also show high stability at high temperature (8). Alkyl-
PTEs are relatively stable under physiological conditions. Shooter et al. (13) injected 
C57BL mice with MNU or ENU and they found that the half-life of Me-PTE induced by 
MNU could be 7 days in kidney, lung and liver, and this number would increase to 10-15 
weeks for Et-PTE induced by ENU. Using an HPLC-based method, Engelse et al. (14) 
compared the half-life of alkyl-PTEs with other base alkylation products in liver tissues of 
rats treated with ENU or N,N-dimethylnitrosamine (DMN), and found that alkyl-PTEs 
persist for more than 56 days. 
 
Sp Rp
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The formation of alkyl-PTEs is also sequence-dependent. Guichard et al. (15), using 
32P postlabeling, showed that tissues of N-nitrosodiethylamine (NDEA)-treated mice 
contains a higher level of Et-PTEs with the 5′-nucleobase being thymine or guanine. Mass 
spectrometry analysis also revealed similar non-random distribution of alkyl-PTEs in 
different flanking sequences contexts in lung tissue DNA of mice treated with tobacco-
specific nitrosoamine NNK and its metabolite NNAL (11).  
Formation of POB- and PHB-phosphotriester 
Many tobacco-specific nitrosamines, including N′-nitrosonornicotine (NNN), NNK  as 
well as its metabolic product NNAL, were characterized as strong carcinogens in various 
laboratory animal studies (16-18), and both NNN and NNK have been classified as group 
1 carcinogens by the International Agency for Research on Cancer (19). Since 2012, several 
studies revealed that phosphate adducts, including methyl (11), pyridyloxobutyl (POB) and 
pyridylhydroxybutyl (PHB) (11,20,21), could be detected in lung tissue of mice treated 
with the aforementioned nitrosamines (22) as well as lung cancer patients (23). The 
pathways for metabolic activation of NNN and NNK are shown in Figure 1-2 (11,20). 
Briefly speaking, after several steps of metabolic reactions, highly-reactive diazonium ions 
(compounds 1 and 2) could pyridyloxobutylate or pyridylhydroxybutylate phosphate 
backbone to form the corresponding POB- or PHB-PTEs. Additionally, one of the 
byproducts, methane diazohydroxide (compound 3) can also react with DNA to form Me-
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PTEs. Similar as alkyl-PTEs, POB- and PHB-PTEs are also highly persistent in vivo, some 
of the PTEs could persist in tissues in over 70 weeks (24), suggesting their potential in 
serving as robust biomarkers for tobacco-induced carcinogenesis.  
 
 
Figure 1-2. Formation of phosphate backbone adducts from metabolic activation of NNN, 
NNK and NNAL.  
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Repair of Alkylphosphotriester Lesions 
The repair mechanism of alkyl-PTEs in vivo is under-investigated. In E. coli cells, 
Me-PTEs are removed by E. coli O6-methylguanine DNA methyltransferase (Ada protein) 
(25). Ada is a 39-kDa protein having a wide range of substrates, including O6-
methylguanine, O4-methylthymine and Me-PTEs. Meanwhile, Ada protein could also 
repair bulky alkylated DNA lesions (n-propyl, i-propyl and n-butyl) formed on the O6 
position of guanine at a lower rate (26).  
The Ada-mediated repair of Me-PTEs proceeds through a zinc- and methylation-
dependent electrostatic switch mechanism, where the methyl group on the phosphate 
backbone would be transferred into Cys-38 (27). In N-ada domain, four cysteine residues, 
Cys-24, -38, -69 and -72, coordinate with a zinc ion to achieve its methyltransferase activity. 
The sulfur atoms situated on the side chains of three cysteines, Cys-24, -69 and -72 form 
hydrogen bond to main chain of Ada protein, eventually stabilizing the structure but 
lessening their reactivity, while Cys-38 could be free from hydrogen bonding interaction, 
resulting in maintenance of its nucleophilicity. Lindahl et al. (28) observed the loss of Ada 
activity accompanied by the formation of methylated cysteine, indicating that Ada works 
as a suicide protein rather than an enzyme, and the methylated protein could be recovered 
upon addition of added external sacrificial reagent, e.g. methanethiol (29). Additionally, 
the repair of Me-PTEs mediated by Ada protein is specific to the Sp diastereomer. This can 
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be explained from the facts that, in B-form duplex DNA, the methyl group on Sp-Me-PTE 
projects into the solution from the phosphodiester backbone, whereas the methyl group on 
Rp diastereomer points inwards into DNA with greater steric crowding. As a result, the Sp 
diastereomer reacts more readily with Cys-38 of Ada protein (30). 
Ada is a bifunctional protein: Apart from being a repair protein, it also works as a 
transcriptional regulator (31). The fact that Ada works as a suicidal protein would suggest 
that its removal of Me-PTEs is expensive and inefficient since one protein molecule could 
only remove one methyl group from the phosphate backbone. It turned out that methylated 
Ada protein could increase the E. coli capability in tolerating alkylating agents (32-34) via 
its interaction with the promoter sequence of ada gene, also known as “ada box” (27), 
followed by increased expression of Ada protein. The ada box is on upstream of RNA 
polymerase-binding site and works as a positive regulator of ada gene (35,36). Aside from 
ada gene, ada box also exists in other genes including alkA, alkB and aidB (37-39), which 
can be upregulated by adaptive response.  
In mammalian cells, so far no repair pathway has been reported to remove alkyl-
PTEs (6). Human O6-methylguanine methyltransferase (MGMT) serves same function as 
E. coli Ada in repairing O6-MedG but it cannot repair alkyl-PTEs (40,41). However, Le Pla 
et al. (42) raise the possibility of repair pathway in mammalian cells. In that study, the half-
life of total Et-PTEs in liver DNA of mice treated with NDEA was measured by HPLC, 
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and an initial sharp decline of Et-PTEs (with t1/2<24h) was found, which is probably 
attributed to active repair pathway. 
Biological Consequences of Alkylphosphotriester Lesions 
Even though the PTEs have come to our sight recently, research about their biological 
consequences still remains overlooked. Since PTE formation could neutralize the negative 
charge on the phosphate backbone, it could interfere with the interaction of proteins to 
DNA substrates. There are many proteins found to be sensitive to PTEs: MutS (43), MutY 
(44), RNA polymerase (45,46) and APE protein, a class-II apurinic/apyrimidinic 
endonuclease (47), etc. 
Even though lacking research in how PTEs affect DNA replication in vivo, several in 
vitro studies infer that existence of PTEs could inhibit replication mediated by many 
polymerases. Miller et al. (48) revealed that an Et-PTE in a 12 mer 
oligodeoxyribonucleotide (ODN) could result in a decreased elongation rate (25 % for 
isomer I and 50 % for isomer II) mediated by E. coli polymerase I. Additionally, subsequent 
in vitro study also indicated that a mixture of 50:50 Sp and Rp of Et-PTE in ODN could 
impede primer extension by T4 DNA polymerase, which could be tolerated by increasing 
dNTP level (49). In addition to influencing polymerase elongation, iPr-PTEs could also 
affect the unwinding process mediated by SF1 helicases in vitro (50). 
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LC-MS/MS-coupled Competitive Replication and Adduct Bypass (CRAB)Assay 
One critical reason about why little attention has been paid on PTEs is the lack of 
suitable and precise analytical methods. PTEs are resistant to many enzymes commonly 
used in biochemistry and molecular studies for analyzing biological sequences, such as T4 
PNK (51), DNase I, nuclease P1 and alkaline phosphatase (52-54), etc. Additionally, 
another major hurdle on PTE research is the lack of the methods for isolating and 
identifying independent Sp and Rp diastereomer-containing ODNs. In this dissertation, a 
HPLC-NMR coupled analysis has been employed to separate and characterize two 
diastereomers of PTE-carrying ODNs, and CRAB assay was utilized for analyzing the 
biological consequences of PTEs. 
Competitive replication and adduct bypass (CRAB) assay was introduced by Dr. 
Essigmann and coworkers (55-57), which allows for the assessment about how a particular 
lesion interferes DNA replication and repair in vivo. In this assay, the lesion-containing 
ODNs (22 mer) or competitor ODN (25 mer, internal standard) are incorporated into 
M13mp7 bacteriophage, and the lesion/competitor ratio can be accurately normalized by 
32P-labeled PAGE gel. After normalization, the lesion-containing or lesion-free control 
vectors are mixed with competitor vector in a specific ratio and transfected into E. coli 
strains proficient or deficient in polymerases or repair protein. After several cycles’ 
proliferation, the replication products of the aforementioned vectors are extracted and 
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purified, followed by PCR amplification and restriction endonuclease digestion to obtain 
short ODNs containing the replication products containing the initial lesion-containing site, 
which can be subjected to PAGE gel analysis to quantify bypass efficiency and mutation 
frequency by the following equation: Bypass efficiency (%) = (lesion signal/competitor 
signal)/(control signal/competitor signal)×100%. A brief workflow is shown on Figure 1-
3. In CRAB assay, what being analyzed is the replication products of lesion-containing 
vectors, as a result, the resistance of PTEs to enzymes can be disregarded. 
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Figure 1-3. The workflow of CRAB assay. 
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Besides CRAB assay, mass spectrometry also becomes a powerful tool for PTE 
analysis due to its high sensitivity and specificity. LC-MS/MS can be coupled with CRAB 
assay to provide unambiguous insight about replication products. First, previous study has 
elucidated how to determine the sequence of ODNs by mass spectrometry (Figure 1-4)(60): 
In MS/MS mode, two types of fragmentation ions, wn and 
               
Figure 1-4. MS/MS fragmentation scheme of ODN. 
 
[an-base] ions, could be generated, and (wn-wn-1) or ([an+1-base]-[an-base]) represents the 
mass-to-charge ratio (m/z) of nucleoside n, and each canonical nucleoside has a unique 
mass. With this method, the sequence of the target ODN can be identified. Second, LC-
MS/MS analysis also made it possible to quantify the relative levels of different replication 
products (61). 
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Electrophoretic Mobility Shift Assay (EMSA) 
Electrophoretic mobility shift assay (EMSA) is a powerful tool for analyzing the 
nucleic acid-protein interactions (62-64). The method is based on the electrophoretic 
mobility difference between free nucleic acids and protein-nucleic acid complex (65). In 
this assay, the nucleic acids are incubated with protein at different concentrations. After 
electrophoresis, free nucleic acid can be separated with protein-nucleic acid complex, and 
the dissociation constant (Kd) can be quantified using the following equation: [Unbound 
nucleic acid]/[Bound nucleic acid]= Kd ×1/ [Protein] (66).  
EMSA is a powerful tool for quantifying binding capacity of a single protein to nucleic 
acid. First, by employing 32P-labeling, the assay can obtain high sensitivity (to ~0.1 nM of 
nucleic acid). Apart from radioisotope-labeling, EMSA is also compatible with other 
labeling strategies, including fluorescence (67) or chemiluminescence (68,69). Second, 
EMSA has less requirement to size or structure of nucleic acids and protein. It has been 
reported that the method is compatible with a broad range of nucleic acids structure [single 
strand, duplex, triplex (70) or circular DNA (71)) or size (from 5 nt (72) to several hundred 
bp (73)], protein size (74) and complexity of protein components (75).   
EMSA, however, also has some disadvantages: The electrophoresis can influence the 
chemical equilibrium of protein-nucleic acid interaction, which can be compensated by low 
temperature and short time for electrophoresis. Moreover, except for dissociation constant, 
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EMSA can provide little information about protein-nucleic acids binding, like the 
sequences of nucleic acids involved in direct interaction with proteins, and other binding 
assays, e.g. quantitative DNase footprint titration (76), are necessary in order for obtaining 
detailed binding information. 
Scope of This Dissertation  
As mentioned above, multiple studies have shown the relationship between formation 
of PTEs and tobacco smoking, suggesting their potential in serving as a persistent 
biomarker for tobacco-related diseases, like lung cancer. In contrast, little is known about 
the biological consequences of PTEs, especially how PTEs influence DNA replication, and 
how they are repaired in vivo. Unlike nucleobase modifications, the structures of PTEs are 
complicated, and many factors, including properties of backbone modifications, 
stereochemistry and sequence contexts, could affect the biological consequences of PTEs.  
In this dissertation, we attempt to attain the following objectives: 1) To synthesize and 
characterize PTEs with different groups (including methyl, ethyl, n-propyl, n-butyl, POB 
and PHB), stereochemistry (Sp and Rp) or flanking base sequences. 2) To reveal how size, 
stereochemistry, flanking base sequences of alkyl-PTEs, and the SOS-induced translesion 
synthesis polymerases (Pol II, Pol IV and Pol V in E. coli) bypass of these lesions in E. 
coli. 3) To define the role of Ada protein in modulating the repair and translesion synthesis 
of alkyl-PTE lesion in E. coli cells. 
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CHAPTER 2 
 
Cytotoxic and Mutagenic Properties of Alkyl Phosphotriester Lesions in Escherichia 
coli Cells 
 
INTRODUCTION 
DNA carries the genetic information, but it has limited chemical stability, where 
spontaneous hydrolysis can result in deamination of nucleobases and cleavage of N-
glycosidic bonds in DNA (1). The integrity of the human genome can also be compromised 
upon exposure to many endogenous and exogenous agents, which may result in 
mutagenesis and carcinogenesis (2,3). 
    Alkylation is a common type of DNA damage (4), and DNA alkylation constitutes the 
major mechanism of action for many commonly prescribed cancer chemotherapeutic 
agents (5). So far, the majority of studies about DNA alkylation have focused on nucleobase 
modifications, which is attributed to the potential mutagenic effects of these lesions (4). 
Aside from forming nucleobase adducts, alkylating agents can also attack one of the non-
carbon-bonded oxygen atoms of internucleotide phosphate group to yield backbone 
alkylation products, i.e. the alkyl phosphotriester (alkyl-PTE) lesions (6). In this vein, Me- 
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and Et-PTE (Figure 2-1) were found to account for 12-17% and 55-57% of the total 
alkylation in duplex DNA treated with N-nitroso-N-methylurea and N-nitroso-N-ethylurea, 
respectively (7). In addition, a very recent study showed that pyridylhydroxybutyl-PTE 
adducts constitute 38-55% and 34-40% of all the measured pyridine-containing DNA 
adducts in lung and liver tissues, respectively, of rats treated through drinking water with 
a tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (8). 
Depending on which of the two non-carbon-bound oxygen atoms on backbone phosphate 
is alkylated, alkyl-PTEs can form in the Sp or Rp configuration (Figure 2-1) (6). 
Alkyl-PTEs are known to persist in mammalian tissues. A previous study showed that, 
in liver tissues of mice, Et-PTE displayed longer half-life (t1/2, up to 32 days) than any 
nucleobase ethylation products (9). Another study by Shooter et al. (10) revealed that the 
t1/2 for Me-PTE was 7 days in kidney and lung tissues of C57BL mice, which is much 
shorter than the t1/2 values for Et-PTE in the same tissues (10-15 weeks). The poorer repair 
of the alkyl-PTE lesions in mammalian tissues suggest that they are more likely to be 
encountered by DNA replication machinery than nucleobase alkylation products.  
The repair and biological consequences of alkyl-PTE lesions are under-investigated (6). 
In this respect, the formation of alkyl-PTEs results in neutralization of the negative charge 
of the phosphate backbone, which interferes with the binding of proteins to DNA, thereby 
resulting in an inhibition of the normal functions of many DNA-binding proteins. For 
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instance, a single isopropyl-PTE could inhibit SF2 family of DNA helicases, including 
RecQ and WRN (11). It was also observed that the Sp, but not the Rp diastereomer of Me-
PTE could be removed by Ada protein in Escherichia coli (12,13). In addition, in vitro 
biochemical studies revealed that a 50:50 mixture of Sp- and Rp-Et-PTE could inhibit 
primer extension mediated by T4 DNA polymerase (14). However, it remains unclear how 
the alkyl-PTE lesions affect DNA replication in cells. 
In the present study, we employed a robust shuttle vector-based method (15,16), 
together with mass spectrometry, to assess how alkyl-PTE lesions with different sizes of 
the alkyl group (from methyl to n-butyl) and stereochemical configurations (Sp and Rp) 
affect the fidelity and efficiency of DNA replication in E. coli cells, and how replication 
across these lesions is influenced by translesion synthesis DNA polymerases and the Ada 
protein. 
MATERIALS AND METHODS 
Materials 
All chemicals, unless specified, were from Sigma-Aldrich (St Louis, MO, USA) or Thermo 
Fisher Scientific (Pittsburg, PA, USA). Common reagents for solid-phase DNA synthesis 
were from Glen Research (Sterling, VA, USA) and all the unmodified 
oligodeoxyribonucleotides (ODNs) were from Integrated DNA Technologies (Coralville, 
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IA, USA). 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) was from Oakwood Products Inc. 
(West Columbia, SC, USA), and [-32P]ATP was obtained from Perkin Elmer (Piscataway, 
NJ, USA). All enzymes were purchased from New England Biolabs (Ipswich, MA, USA). 
M13mp7(L2) plasmid, wild-type AB1157 E. coli strains, C215 E. coli strains and Ada-
deficient E. coli strains were kindly provided by Prof. John M. Essigmann (17,18). 
Polymerase-deficient AB1157 strains [Δpol B1::spec (Pol II deficient), ΔdinB (Pol IV-
deficient), ΔumuC::kan (Pol V deficient) and Δpol B1::spec ΔdinB ΔumuC::kan (Pol II, Pol 
IV, Pol V-triple knockout)] were generously provided by Prof. Graham C. Walker (17). 
Chemical Synthesis  
The thymidine alkylphosphoramidites were synthesized following previously published 
procedures (Scheme 2-1) (19,20). Compound 1 (200 mg, 0.75 mmol) was dissolved in 
anhydrous diethyl ether (7 ml) in an ice bath under argon atmosphere, to which solution 
were added the corresponding alcohol (140 μl) and triethylamine (4.0 eq., 306 mg). The 
solution was stirred at room temperature overnight, mixed with 8 ml petroleum ether, and 
filtered. The resulting precipitate was washed with ether. The filtrate and the ether solution 
were pooled and evaporated under reduced pressure to yield 2a-b, which were employed 
directly for the synthesis in the next step. 
For the preparation of compounds 2c-d, compound 1 (300 mg, 1.13 mmol) in 2 ml 
tetrahydrofuran, the corresponding alcohol (140 μl) and triethylamine (230 μl, 1.63 
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mmol) were added to a round bottom flask, which was under an argon atmosphere and 
placed in an ice water bath. The solution was stirred at room temperature for 1 h and 
filtered. The filtrate was concentrated in vacuo. Pentane (10 ml) was added to the 
resulting solid, and the mixture was filtered. The solvent in the filtrate was removed 
under vacuum to yield compounds 2c-d. 
For dimethoxytrityl (DMTr) protection of the 5-hydroxyl group, compound 4 was 
prepared following the previously published procedures (21). Briefly, compound 3 (100 
mg, 0.41 mmol) was dissolved in anhydrous pyridine (10 ml), and to the mixture were 
added dimethoxytrityl chloride (1.5 eq.) and 4-dimethylaminopyridine (0.5% mol). After 
stirring at room temperature for 10 h, the solution was concentrated in vacuo and the 
residues were purified with silica gel column chromatography by using ethyl acetate as 
the mobile phase to yield compound 4. 
For phosphoramidite building block synthesis, to a round bottom flask, which 
contained a solution of compound 4 (70 mg, 0.13 mmol) in dry dichloromethane (1.5 ml), 
were added compound 2a-b (1 eq.) and diisopropylamine hydrotetrazolide (1 eq.), and 
the mixture was stirred at room temperature under argon. After 1 h, TLC analysis 
indicated complete conversion of the starting material. The solvent was removed in vacuo 
and isolated by silica gel column chromatography with a mixture of hexane, ethyl acetate, 
and triethylamine (49:49:2, v/v) to yield the desired products 5a-b. 
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For the syntheses of compounds 5c-d, compound 2c-d (1 eq.) and tetrazole in 
acetonitrile (0.3 ml, 0.135 mmol) were added to a round bottom flask containing a 
solution of compound 4 (70 mg, 0.13 mmol) in dry dichloromethane (1.5 ml), and the 
mixture was stirred at room temperature under argon atmosphere. The reaction was 
continued for 5 h, and the desired products 5c-d were purified following the 
aforementioned procedures for compounds 5a-b. 
The reaction yields and spectroscopic characterizations of the above-synthesized 
products are provided in the online Supplementary Materials. The nuclear magnetic 
resonance (NMR) spectra for these compounds are shown in Figures 2-2 and 2-3. 
ODN synthesis 
The 12-mer lesion-containing ODNs, 5-ATGGCT(X)TGCTAT-3 (‘X’ designates the 
location of the alkyl-PTE), and Me-PTE-containing dimer 5-T(Me)T-3 were synthesized 
on a Beckman Oligo 1000M DNA synthesizer (Fullerton, CA) at 1 μmol scale. The 
corresponding phosphoramidite building block was dissolved in anhydrous acetonitrile at 
a concentration of 0.067 mM. Commercially available ultramild phosphoramidite 
building blocks were used for the incorporation of unmodified nucleotides (Glen 
Research Inc., Sterling, VA, USA) following the standard ODN assembly protocol. The 
ODNs were cleaved from the controlled pore glass support and deprotected with 
concentrated ammonium hydroxide at room temperature for 55 min. The solvent was 
29 
 
removed by using a Speed-vac, and the resulting solid residues were redissolved in water 
and purified by high-performance liquid chromatography (HPLC).  
HPLC 
The HPLC separation was performed on an Agilent 1100 system with a Kinetex XB-C18 
column (4.6 × 150 mm, 5 μm in particle size and 100 Å in pore size; Phenomenex Inc., 
Torrance, CA, USA). For the purification of the synthesized 12-mer ODNs, the mobile 
phases consisted of 50 mM triethylammonium acetate (pH 7.0, Solution A) and a mixture 
of solution A and acetonitrile (70/30, v/v, Solution B). A gradient of 5-30% B in 5 min 
and 30-60% B in 65 min was employed, and the flow rate was 0.7 ml/min. The HPLC 
traces for the purification of the 12-mer lesion-containing ODNs are shown in Figure 2-6 
and the electrospray ionization-mass spectra (ESI-MS) and tandem MS (MS/MS) of these 
ODNs are displayed in Figures 2-7 to 2-10. 
Determination of stereochemical configurations of Me-PTE-containing ODNs 
The Me-PTE-containing dimer 5-T(Me)T-3 was first purified by HPLC using a Synergi 
Fusion-RP column (10 × 150 mm, 4 μm in particle size and 80 Å in pore size; 
Phenomenex Inc., Torrance, CA, USA). The mobile phases were water (Solution A) and 
methanol (Solution B). A gradient of 5-25% B in 5 min and 25-50% B in 75 min was 
used, and the flow rate was 1.1 ml/min. The HPLC traces are shown in Figure 2-4a and 
30 
 
the products were identified by MS and 31P-NMR. For NMR analyses, the two purified 
diastereomers were dissolved in 300 μl CD3OD, and triphenylphosphine was added as the 
reference for chemical shift calibration. The 31P-NMR spectra were recorded on a Bruker 
Avance Neo 400 spectrometer at 80 MHz for 31P (Figure 2-4b, c). 
To determine the stereochemical configurations of the Me-PTEs in 12 mer ODNs, 
we digested the lesion-containing ODNs with a cocktail of four enzymes and analyzed 
the digestion mixture by HPLC to examine whether the two diastereomers in 12 mer 
ODNs exhibited the same elution order as those in the dimers. The digestion was 
conducted following previously published procedures (22). Briefly, nuclease P1 (0.1 
U/μg DNA), phosphodiesterase 2 (0.000125 U/μg DNA), and 1 nmol of 12 mer ODNs 
with Sp- or Rp-Me-PTE were incubated in a 100-μl solution containing 300 mM sodium 
acetate (pH 5.6) and 10 mM ZnCl2. After incubation at 37C for 24 h, alkaline 
phosphatase (0.1 U/μg DNA), phosphodiesterase 1 (0.00025 U/μg DNA), and 50 μl of 
0.5 M Tris-HCl (pH 8.9) were added to the digestion mixture, and the mixture was 
incubated at 37C for 2 h. The enzymes were subsequently removed by chloroform 
extraction and the solution was dried by lyophilization. The resulting solid residue was 
reconstituted in doubly distilled water (100 μl) and analyzed by HPLC. A Thermo 
Hypersil Gold C18 column (4.6250 mm, 3 μl in particle size, 300 Å in pore size, 
Thermo Scientific Inc., Waltham, MA) was employed for the separation of the digestion 
31 
 
mixture. A solution of 10 mM ammonium formate and methanol were used as mobile 
phases A and B, respectively. The gradient profile was 0% B in 42 min, 0-2% B in 1 min, 
2% B for 17 min, 2-5% B in 1 min, 5-25% B in 5 min, 25-35% B in 75 min. The HPLC 
traces are shown in Figure 2-5. 
Construction of single-stranded lesion-containing and lesion-free competitor M13 
genomes 
The 12-mer alkyl-PTE-containing ODNs were 5-phosphorylated and ligated with a 10-
mer ODN (5-ACTGGAAGAC-3) in the presence of ligation buffer with T4 DNA ligase 
and ATP at 16C for 8 h. The resulting 22-mer ODNs were purified by denaturing 
polyacrylamide gel. 
The lesion-containing and lesion-free M13mp7 (L2) genomes were prepared 
following previously reported procedures (21,23). First, 20 pmol of M13 plasmid was 
digested with 40 U EcoRI-HF at room temperature for 8 h to linearize the vector. The 
linearized vector was mixed with 2 scaffolds, 5-
CTTCCACTCACTGAATCATGGTCATAGCTTTC-3 and 5-
AAAACGACGGCCAGTGAATTATAGC-3 (25 pmol), each spanning one end of the 
linear vector. To the mixture was subsequently added 30 pmol of 5-phosphorylated 22-
mer lesion-containing ODN or 25-mer competitor ODN (5-
GCAGGATGTCATGGCGATAAGCTAT-3). The resulting mixture was treated with T4 
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DNA ligase at 16C for 8 h, followed by incubation with T4 DNA polymerase (22.5 U) at 
16C for 2.5 h to degrade the unligated vector and excess scaffolds. The lesion-containing 
and lesion-free plasmids were purified using Cycle Pure Kit (Omega) and subsequently 
normalized against the competitor plasmid, following published procedures (21,23). 
Transfection of lesion-free, lesion-containing and competitor plasmids into E. coli cells 
The lesion-free or lesion-containing M13 genome was mixed with the competitor genome 
at a 1:1 molar ratio. The mixtures were transfected into SOS-induced, electrocompetent 
AB1157 E. coli strain as well as the isogenic cells deficient in Pol II, Pol IV, Pol V, or all 
three in combination. The lesion-free or lesion-containing M13 genome was also mixed 
with the competitor genome at a 4:1 molar ratio and transfected into electrocompetent 
Ada-proficient (C215) and Ada-deficient (C217) E. coli cells, as described elsewhere 
(21). The SOS induction was conducted by irradiating E. coli cells with 254 nm 
ultraviolet light at a dose of 45 J/m2 (17). The AB1157, C215 and C217 E. coli cells were 
then grown in lysogeny broth (LB) medium at 37C for 5.5 h. The phage was recovered 
from the supernatant by centrifugation at 13200 r.p.m. for 5 min and further transfected 
into SCS110 cells to increase the progeny/lesion-genome ratio. The amplified phage was 
purified by Qiaprep Spin M13 Kit (Qiagen) to obtain the ssM13 DNA template for PCR 
amplification. 
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Quantification of bypass efficiencies and mutation frequencies 
A modified version of the competitive replication and adduct bypass (CRAB) assay 
(15,16,23,24) was employed to assess the bypass efficiencies and mutation frequencies of 
the alkyl-PTE lesions in E. coli cells. The sequence region of interest in the M13 template 
was amplified by PCR with the use of Phusion high-fidelity DNA polymerase. The 
primers were 5-YCAGCTATGACCATGATTCAGTGAGTGGA-3 and 5-
YTCGGTGCGGGCCTCTTCGCTATTAC-3 (‘Y’ denotes the H2N(CH2)6- group 
conjugated to the 5 phosphate group of the ODNs). The amplification started from 
annealing at 98C for 30 s, followed by 35 cycles of amplification, each of which 
consisted of 10 s at 98C, 30 s at 65C and 15 s at 72C, and then with a final 5-min 
extension at 72C and ending at 4C. The PCR products were purified by using Cycle 
Pure Kit (Omega). For determining the bypass efficiencies and mutation frequencies, 100 
ng of PCR products were digested with 10 U BbsI-HF restriction endonucleases together 
with 10 U recombinant shrimp alkaline phosphatase (rSAP) in 10 μl CutSmart buffer 
(New England Biolabs) at 37C for 25 min, followed by heating at 80C for 10 min to 
deactivate the phosphatase. To the mixture were subsequently added 5 mM DTT, 1.66 
pmol [γ-32P] ATP, 10 U T4 polynucleotide kinase (T4 PNK), T4 PNK buffer and water to 
give a total volume of 15 μl. After a 30-min incubation at 37C, the T4 PNK was 
deactivated by heating the solution at 80C for 10 min. To the resulting solution was 
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added 10 U MluCI restriction endonuclease, and the mixture was then incubated at 37C 
for 25 min. The reaction was subsequently quenched by adding 15 μl formamide gel 
loading buffer which contained xylene cyanol FF and bromophenol blue dyes. The 
mixture was resolved by using 30% native polyacrylamide gel (acrylamide:bis-
acrylamide = 19:1), and the gel band intensities were determined by phosphorimager 
analysis on a Typhoon 9410 variable-mode imager.  
The two-step restriction endonuclease digestion gave rise to a 10-mer duplex 
d(p*GGCMNGCTAT)/d(AATTATAGCY), where ‘M’ and ‘N’ designate the nucleobases 
at the dinucleotide sites initially flanking the alkyl-PTE lesions, ‘Y’ is the complementary 
base of ‘N’ in the opposite strand, and p* denotes the [5-32P]-labeled phosphate. The 
bypass efficiency was calculated by using following equation: Bypass efficiency (%) = 
(lesion signal/competitor signal)/(control signal/competitor signal)×100%. 
Identification of mutagenic products by LC-MS and MS/MS 
The PCR products were digested with 50 U BbsI-HF restriction endonuclease and 20 U 
rSAP in 250 μl CutSmart buffer at 37C for 2 h, and the phosphatase was subsequently 
deactivated by heating at 80C for 20 min. To the mixture was added 50 U MluCI and the 
solution was incubated at 37C for 1 h. The solution was then extracted once with 
phenol/chloroform/isoamyl alcohol (25:24:1, v/v). The aqueous layer was dried, desalted 
by HPLC and redissolved in 20 μl water. A 10-μl aliquot was injected for LC-MS/MS 
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analysis on an LTQ linear ion trap mass spectrometer (Thermo Electron, San Jose, CA, 
USA). An Agilent Zorbax SB-C18 column (0.5 × 250 mm, 5 μm in particle size) was 
employed, and the gradient for LC-MS/MS analysis was 5 min of 5–20% methanol 
followed by 35 min of 20–50% methanol in 400 mM HFIP (pH was adjusted to 7.0 with 
triethylamine). The mass spectrometer was set up for monitoring the fragmentation of the 
[M-3H]3- ions of 10-mer d(GGCMNGCTAT) and d(AATTATAGCY), with ‘M’, ‘N’, and 
‘Y’ being ‘A’, ‘T’, ‘C’ or ‘G’. The fragment ions detected in MS/MS were manually 
assigned.  
RESULTS 
The objectives of this study were to assess how alkyl-PTE lesions with different 
stereochemical configurations and various sizes of alkyl group compromise DNA 
replication, and to define the respective roles of the three SOS-induced polymerases and 
Ada protein in bypassing and repairing these lesions in E. coli cells.  
We first synthesized 12-mer ODNs harboring a site-specifically inserted alkyl-PTE 
lesion (Scheme 2-1) and characterized these ODNs by ESI-MS and MS/MS analyses 
(Figures 2-7 to 2-10). The ESI-MS and MS/MS results support the site of the alkyl-PTE 
lesion and the identity of the alkyl group being conjugated with backbone phosphate. In 
addition, we established the configurations of the two diastereomers of Me-PTEs based on 
31P-NMR and HPLC analyses (Figures 2-4 to 2-5). Previously, Weinfeld et al. (13,25) 
36 
 
showed that, under the same solvent conditions, the 31P signal for the Sp diastereomer of 
Me-PTE appeared at a lower field than that for the Rp counterpart. We first determined the 
stereochemistry of the Me-PTE-containing T(Me)T based on 31P-NMR analyses, where the 
earlier and later eluting T(Me)T-1 and T(Me)T-2 were found to contain the Sp and Rp 
diastereomers of the Me-PTE, respectively. A chemical shift difference of 0.16 ppm for the 
two diastereomers was nearly identical to what was previously reported (26). We next 
digested the HPLC-purified Me-PTE-containing 12-mer ODNs with a cocktail of four 
enzymes, which release Me-PTE as T(Me)T. By comparing the HPLC elution properties 
of the T(Me)T liberated from the 12-mer ODNs with those of the standards, we 
demonstrated that the earlier- and later-eluting 12-mer ODNs contained the Sp- and Rp-Me-
PTEs, respectively. Based on the observations that the Sp- and Rp-Me-PTE lesions in a 
dimer and a 12-mer ODN exhibit the same elution orders on reversed-phase HPLC columns, 
we assign the stereochemistry of the purified Et-, nPr- and nBu-PTEs based on their relative 
orders of elution from the HPLC column, i.e., the Sp diastereomer elutes earlier than the Rp 
diastereomer. 
We next ligated these lesion-containing ODNs into single-stranded M13mp7 plasmid 
and measured the bypass efficiencies and mutation frequencies of the alkyl-PTE lesions 
using a modified version of the competitive replication and adduct bypass assay (Figures 
2-11 to 2-16) (15,16). After PCR amplification and restriction digestion, the released ODNs 
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were analyzed by LC-MS/MS and native PAGE to identify the replication products, as 
described elsewhere (24). As shown in Figure 2-11, we were able to radiolabel the 5 
terminus of either the original lesion-situated strand, i.e. d(p*GGCMNGCTAT), or its 
complementary strand, i.e. d(p*AATTATAGCY), by switching the orders of BbsI and 
MluCI digestions. Results from native PAGE analyses of the resulting radiolabeled 
fragments revealed that the Sp diastereomer of Me-PTE could give rise to TT→GT and 
TT→GC mutations at the flanking TT dinucleotide sites, whereas no mutagenic products 
were detectable for any other alkyl-PTE lesions. In this regard, when BbsI was added first, 
we could resolve [5-32P]-labeled d(p*GGCTTGCTAT) (non-mutagenic product, 10 mer 
TT) from the products with TT→GT or TT→GC mutation, i.e. d(p*GGCGTGCTAT) (10 
mer GT) and d(p*GGCGCGCTAT) (10 mer GC). Nonetheless, 10 mer GT and 10 mer GC 
could not be distinguished by native PAGE analysis (Figure 2-11b). To resolve these two 
mutagenic products, we first added MluCI to radiolabel the opposite strand, which enabled 
us to separate the product with TT→GT mutation, i.e. d(p*AATTATAGCA) (10 mer A), 
from that with TT→GC mutation, namely d(p*AATTATAGCG) (10 mer G), as shown in 
Figure 2-11c and Figures 2-12 to 2-14.  
    We further confirmed the identities of the aforementioned restriction digestion 
products by LC-MS/MS analysis. We monitored the [M-3H]3- ions of d(GGCMNGCTAT) 
and d(AATTATAGCY), where ‘M’ and ‘N’ designate the nucleotides inserted at the initial 
38 
 
TT dinucleotide flanking the alkyl-PTE site, and ‘Y’ represents the opposing nucleotide of 
‘N’ in the complementary strand, respectively (Figures 2-15, 2-16). The LC-MS/MS data 
showed that only Sp-Me-PTE could induce TT→GT and TT→GC mutations, which are in 
keeping with the results obtained from the aforementioned PAGE analyses. 
Having identified the replication products, we determined the bypass efficiencies of 
the alkyl-PTE lesions by measuring the ratio of combined intensities of all 10-mer bands 
arising from the lesion-containing genome over that of the 13-mer band emanating from 
the lesion-free competitor genome (see Materials and Methods). The results showed that 
the Sp diastereomers of all four alkyl-PTEs do not appreciably impede DNA replication in 
E. coli cells, whereas the Rp diastereomers elicit moderate blockage effects on DNA 
replication (Figure 2-17a).  
We also examined the roles of the three SOS-induced polymerases (i.e. Pol II, Pol IV 
and Pol V) in bypassing the alkyl-PTE lesions by conducting the replication experiments 
using the isogenic E. coli strains that are deficient in these polymerases. The results showed 
that the bypass of the alkyl-PTE lesions does not require any of the three TLS polymerases 
(Figure 2-17a). Moreover, our results showed that the bypass efficiencies of these lesions 
were not modulated by SOS induction, either in wild-type AB1157 cells or the isogenic 
cells with all three SOS-induced DNA polymerases being knocked out (Figure 2-17a). 
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We further determined the mutation frequencies of the Me-PTE in wild-type and 
polymerase-deficient AB1157 E. coli strains (Figure 2-17b). It turned out that the Sp-Me-
PTE is moderately mutagenic, resulting in TT→GT and TT→GC mutations. Additionally, 
deletion of any of the three SOS-induced polymerases alone did not confer any significant 
alterations in mutation frequencies, though simultaneous removal of the three polymerases 
in both SOS-induced and uninduced cells led to a slight, albeit statistically significant 
decrease in TT→GT mutation (Figure 2-17b). 
The unique mutagenic property of Sp-Me-PTE parallels the previous finding that Ada 
protein removes the methyl group exclusively from the Sp-Me-PTE at an efficiency that is 
much higher than the corresponding removal of larger alkyl groups from alkyl-PTE lesions 
(13). Thus, we next asked whether Ada protein assumes any role in modulating the 
cytotoxic and mutagenic properties of the two diastereomers of Me- and Et-PTEs by 
conducting replication experiments with the use of isogenic E. coli cells that are proficient 
or deficient in Ada protein (Figure 2-18). Our results showed that the deletion of Ada led 
to a significant decline in bypass efficiency for Sp-Me-PTE, which is accompanied with the 
abrogation of both TT→GT and TT→GC mutations for the lesion, suggesting the 
involvement of Ada protein in repairing the Sp-Me-PTE and inducing mutations for this 
lesion. Similar as what we found for AB1157 cells, replication across Sp-Me-PTE and the 
two diastereomers of Et-PTE lesions are error-free in Ada-deficient C217 cells, and 
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deletion of Ada protein did not appreciably alter the bypass efficiencies of these three 
lesions (Figure 2-18). 
DISCUSSION 
We systematically investigated the cytotoxic and mutagenic properties of alkyl-PTE 
lesions in E. coli cells and our results led to several important conclusions. First, we found 
that the Sp and Rp diastereomers of the alkyl-PTE lesions exerted distinct effects on DNA 
replication in E. coli cells. The lesions in the Sp configuration displayed higher replication 
bypass efficiencies than the corresponding unmodified DNA, whereas those in the Rp 
configuration suppress DNA replication in AB1157 cells. The replication bypass 
efficiencies for the Sp-alkyl-PTEs, except for the methyl adduct which is removed by Ada 
protein, decrease with the size of alkyl group, which might be attributed to the elevated 
steric hindrance imposed by larger alkyl groups. In duplex DNA, the alkyl group in the Sp 
diastereomer is known to point perpendicularly out from the DNA double helix, whereas 
that of the Rp diastereomer projects into the major groove (6). Hence, the alkyl groups in 
the Sp configuration may assume some favorable interaction with DNA polymerases to 
promote translesion synthesis, where steric hindrance imposed by larger alkyl groups may 
diminish this enhancement effect. However, the Rp-alkyl-PTE lesions display an opposite 
trend, with nPr- and nBu-PTEs exhibiting higher bypass efficiencies than Me- and Et-PTEs. 
This result supports that the difference in stereochemical configurations of the alkyl group 
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conjugated with the phosphate backbone can modulate the replicative bypass of these 
lesions. By employing a DNA template containing an equimolar mixture of Sp and Rp 
diastereomers of Et-PTE at a defined site, Tsujikawa et al.(14) found that the lesions could 
inhibit partially primer extension catalyzed by T4 DNA polymerase, but could be bypassed 
by E. coli DNA polymerase I. The results from that study also suggested that one of the 
two diastereomers was a major block to DNA replication (14), though the identity of the 
diastereomer could not be ascertained owing to the lack of stereochemically pure DNA 
substrates. It is worth noting that, due to the differential accessibilities of the two non-
carbon-bound oxygen atoms on backbone phosphate to DNA alkylating agents, the Sp 
diastereomer is produced at a higher yield than the Rp counterpart (27). Hence, the 
assessment about overall biological consequences of alkyl-PTEs should also take into 
account the relative frequencies of occurrence of these lesions. 
Second, our results demonstrated that the bypass efficiencies of the alkyl-PTE lesions 
were not affected by deletion of any of the three SOS-induced TLS polymerases, alone or 
all three in combination. Additionally, the mutation frequencies induced by Sp-Me-PTE 
were not influenced by the deletion of any of the three TLS polymerases alone, though the 
absence of all three polymerases resulted in a slight, yet statistically significant decrease in 
the frequency of TT→GT mutation. 
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Third, Ada protein, which could repair the Sp-Me-PTE, is required for the TT→GT 
and TT→GC mutations induced by this lesion. The removal of Me-PTE by Ada protein 
takes time. In this vein, we also measured the bypass efficiencies and mutation frequencies 
of the two diastereomers of Me-PTEs at 1, 3 and 6 h following transfection, and we 
observed that at 1 h, the bypass efficiency of Sp-Me-PTE at 1 h is lower than that at 3 and 
6 h (Figure 2-19). Ada protein plays a crucial role in bacterial tolerance toward exposure 
to alkylating agents in a process known as adaptive response, where Ada acts both as a 
DNA repair protein and a transcription activator (4,28,29). In that process, the 39 kDa Ada 
protein undergoes proteolysis at the sole Lys-Gln linkage to yield a 19 kDa C-terminal 
fragment (C-Ada) and a 20 kDa N-terminal fragment (N-Ada); while Cys321 in C-Ada is 
a methyltransferase for the repair of O6-methylguanine and O4-methylthymine (30), Cys38 
in N-Ada could remove the methyl group specifically from the Sp-Me-PTE (31). Moreover, 
He et al. (31) illustrated, from detailed solution (NMR) and crystal (X-ray) structure studies, 
that this latter methyl group transfer stimulated the binding of N-Ada with DNA through 
an electrostatic switch mechanism. The heightened DNA affinity led to promoter binding 
and transcriptional activation of several genes that are important in repairing alkylated 
DNA lesions including Ada, Aid, AlkA, and AlkB (6). Thus, Ada protein is instrumental in 
protecting the genomic integrity of bacterial cells by promoting the repair of alkylated DNA 
lesions. Here we made an unexpected finding that, while the Ada-stimulated repair of the 
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Sp-Me-PTE results in enhanced replicative bypass, it comes at an expense by inducing 
TT→GT and TT→GC mutations at the flanking nucleoside sites. Further studies are 
warranted for understanding how the selective interaction between Ada and Sp-Me-PTE 
would interfere with Watson-Crick base pairing during DNA replication and trigger 
specific mutations at the lesion site.  
A recent genome-wide mutation analysis of 32 E. coli strains treated with N-methyl-
N'-nitrosoguanidine showed that, among the 4099 identified mutations, 96.6%, 2.17% and 
0.46% were G→A, T→C and T→G substitutions, respectively (32). While G→A and T→C 
mutations are thought to arise from methylation at the O6 of guanine and O4 of thymine 
(21,33), respectively, our results suggest that T→G mutation may be attributed, in part, to 
the Me-PTE formed on the 3' side of thymidine. In this context, it is worth noting that the 
formation frequency of the Me-PTE lesions was found to be affected by flanking sequences 
(34), and flanking sequences may also modulate the mutagenic properties of alkyl-PTE 
lesions. Thus, it will be important to investigate how the cytotoxic and mutagenic 
properties of the alkyl-PTE lesions are influenced by flanking sequences in the future.  
In summary, our study demonstrated that the two diastereomers of alkyl-PTEs exert 
distinct effects on DNA replication; the Sp-alkyl-PTEs did not appreciably impede DNA 
replication, whereas the Rp counterparts could moderately inhibit this process. We also 
revealed that the mutagenic properties of the Sp-Me-PTE could be substantially modulated 
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by Ada protein, but not by any of the three SOS-induced polymerases. Hence, our 
systematic shuttle-vector study on alkyl-PTE lesions offered new insights about how this 
group of DNA alkylation products are recognized by the E. coli DNA replication machinery. 
It will be important to examine how the alkyl-PTE lesions compromise DNA replication in 
mammalian cells in the future. 
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FIGURES AND SCHEMES 
 
Scheme 2-1. Syntheses of alkylphosphoramidite building blocks. Reagents and 
conditions: (a) for methyl and ethyl: ROH, triethylamine, diethyl ether, ice bath, 14 h; for 
n-propyl and n-butyl: ROH, triethylamine, THF, 0C,1 h; (b) DMTr-Cl, DMAP, pyridine, 
room temperature, 10 h; (c) for methyl and ethyl: diisopropylamine hydrotetrazolide, 
CH2Cl2, room temperature, 1 h; for n-propyl and n-butyl: 0.45 M tetrazole in acetonitrile, 
CH2Cl2, room temperature, 5 h. 
  
1 2a-d
3 4
5a-d
a:R=Me  b:R=Et
c:R=nPr d:R=nBu
a
b
c
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Figure 2-1. Sp and Rp diastereomers of alkyl phosphotriester residues in DNA. 
 
 
 
 
 
 
 
 
 
 
 
 
X= -CH3 Me-PTE
-CH2CH3 Et-PTE
-(CH2)2CH3 nPr-PTE
-(CH2)3CH3 nBu-PTE
Sp Rp
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Figure 2-2. The 1H NMR (400 MHz, CDCl3, 25°C) and 31P NMR (80 MHz, CDCl3, 25°C) 
spectra of dT-ethylphosphoramidite. 
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Figure 2-3. The 1H NMR (400 MHz, CDCl3, 25°C) and 31P NMR (80 MHz, CDCl3, 25°C) 
spectra of dT-n-prophosphoramidite 
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Figure 2-4. (a) The HPLC trace for the purification of T(Me)T-dimer and 31P NMR 
spectrum of the Sp-T(Me)T-1 (b) and Rp-T(Me)T-2 (c) (80 MHz, MeOD, 25ºC). 
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Figure 2-5. The HPLC traces for the separation of Sp-T(Me)T and Rp-T(Me)T in the 
digestion mixtures of synthesized 12mer site-specific lesion-containing ODN (5-
ATGGCT(Me)TGCTAT-3). ‘dC’, ‘dG’, ‘dT’, ‘dA’ represent 2'-deoxycytidine, 2'-
deoxyguanosine, thymidine, and 2'-deoxyadenosine, respectively. (a) The HPLC trace for 
the separation of the synthesized T(Me)T dimer together with canonical 2-
deoxynucleosides. (b) The HPLC trace for separation of the Sp-T(Me)T standard. (c) The 
HPLC trace for the separation of the Rp-T(Me)T standard. (d) The HPLC trace for the 
separation of the digestion mixture of 5-ATGGCT(MeSp)TGCTAT-3. (e) The HPLC trace 
for the separation of the digestion mixture of 5-ATGGCT(MeRp)TGCTAT-3. 
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Figure 2-6. HPLC traces for the separations of the synthesized 12mer alkyl 
phosphotriester-bearing ODNs: (a) methyl; (b) ethyl; (c) n-propyl; (d) n-butyl.  
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Figure 2-7. ESI-MS & MS/MS characterizations of d(ATGGCT(MeSp)TGCTAT): (a) 
Negative-ion ESI-MS; (b) the product-ion spectrum of the [M-3H]3- ion (m/z 1221.0) 
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Figure 2-8. ESI-MS & MS/MS characterizations of d(ATGGCT(EtSp)TGCTAT): (a) 
Negative-ion ESI-MS; (b) the product-ion spectrum of the [M-3H]3- ion (m/z 1225.4) 
 
700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
m/z
0
50
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
(%
)
735.1
1225.4
1838.3
919.0
[M-2H]2-
[M-3H]3-
[M-4H]4-
[M-5H]5-a
400 600 800 1000 1200 1400 1600 1800 2000
m/z
0
50
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
(%
)
1148.5
938.4
1405.11096.1 1240.5
714.3
1372.5
1313.1
1609.6
634.4
a3-G
w3
a4-G
w7
2-
[a8-G]
2-
w4
w8
2-
[a9-C]
2-
a5-C
w9
2-
A T G G C T (EtSp) T G C T A T
a
3
-G
w
3
a
4
-G
a
5
-C
w
4
w
9
w
8
w
7
a
8
-G
a
9
-C
w2
w
2
a
1
1
-A
[a11-A]
2-
w
1
1
w11
3-
1043.4
1147.7
1227.4
b
55 
 
 
Figure 2-9. ESI-MS & MS/MS characterizations of d(ATGGCT(nPrSp)TGCTAT): (a) 
Negative-ion ESI-MS; (b) the product-ion spectrum of the [M-3H]3- ion (m/z 1230.4) 
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Figure 2-10. ESI-MS & MS/MS characterizations of d(ATGGCT(nBuSp)TGCTAT): (a) 
Negative-ion ESI-MS; (b) the product-ion spectrum of the [M-3H]3- ion (m/z 1235.2) 
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Figure 2-11. Restriction enzyme digestion and radiolabeling, followed by native PAGE 
(30%) analysis for quantifying the bypass efficiencies and mutation frequencies of alkyl 
phosphotriester lesions in wild-type AB1157 E. coli cells. (a) Selective labelling of the 
original lesion-containing strand and its complementary strand via sequential restriction 
digestion. ‘SAP’ and ‘PNK’ represent shrimp alkaline phosphatase and T4 polynucleotide 
kinase, respectively. ‘MN’ in the sequence denotes the site where the TT dinucleotide 
flanking the alkyl phosphotriester lesions were initially situated.  (b) Gel image showing 
the 13 mer (competitor genome) and 10 mer (control or lesion-containing genome) 
digestion products formed from the original strand, where 10 mer TT, 10 mer GC and 10 
mer GT designate [5-32P]-labeled standard ODNs 5-GGCMNGCTAT-3, with MN being 
TT, GC and GT, respectively. (c) Gel image showing 13 mer (competitor genome) and 10 
mer (control or lesion-containing genome) digestion products formed from the opposite 
strand, where 10 mer A and 10 mer G designate the [5-32P]-labeled standard ODNs 5- 
AATTATAGCY-3, with Y being A and G, respectively. 
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Figure 2-12. Native PAGE (30%) for monitoring the bypass efficiencies and mutation 
frequencies of Sp- and Rp-methyl phosphotriester in wild-type (WT), SOS-WT, SOS-ΔPol 
II, IV, V and triple knockout (TKO) AB1157 E. coli cells. (a) Selective labelling of 
original lesion-containing strand and its complementary strand via sequential restriction 
digestion. ‘SAP’ and ‘PNK’ represent shrimp alkaline phosphatase and T4 polynucleotide 
kinase, respectively. (b) Gel image showing the 13-mer and 10-mer products released 
from the top-strand (lesion-containing strand) of the PCR products of the progeny of the 
competitor genome and the control or lesion-carrying genome, where 10mer TT, 10mer 
GC, and 10mer GT represent the [5′-32P]-labeled standard ODNs 5′-GGCMNGCTAT-3′, 
with ‘MN’ being TT, GC and GT, respectively. (c) Gel images showing the 13-mer and 
10-mer products released from the bottom-strand (opposite to the lesion-containing 
strand) of the PCR products of the progeny of the competitor genome and the control or 
lesion-carrying genome, where 10mer A and 10mer G represent the [5′-32P]-labeled 
standard ODNs 5′-AATTATAGCA-3′ and 5′-AATTATAGCG-3′, respectively.  
WTWT-SOSΔPol II-SOS
ΔPol IV-SOSΔPol V-SOSTKO-SOS ΔPol IV-SOSΔPol V-SOSTKO-SOS
WTWT-SOSΔPol II-SOS
b c
5’-AT GGCMNGCTAT pAATTCA-3’
3’-TACCGX YCGATATTAAp GT-5’
5’-AT pGGCMNGCTAT AATTCAC-3’
3’-TACCGXpYCGATATTAA GTG-5’
5’-ATGGCMNGCTATAATTCA-3’
3’-TACCGXYCGATATTAAGT-5’
MluCIBbsI
BbsI
SAP
[-32P]ATP + PNK
MluCI
MluCI
SAP
[-32P]ATP + PNK
BbsI
a
60 
 
 
Figure 2-13. Native PAGE (30%) for monitoring the bypass efficiencies and mutation 
frequencies of n-propyl and n-butyl phosphotriester in wild-type AB1157 cells without 
SOS induction (WT), or wild-type AB1157 (SOS-WT) and isogenic cells that are 
deficient in Pol II, Pol IV, or PolV (ΔPol II-SOS, ΔPol IV-SOS, ΔPol V-SOS) and all 
three polymerases (TKO-SOS) with SOS induction. (a) Selective labelling of original 
lesion-containing strand via sequential restriction digestion. ‘SAP’ and ‘PNK’ represent 
shrimp alkaline phosphatase and T4 polynucleotide kinase, respectively. (b) Gel image 
showing the 13-mer and 10-mer products released from the top-strand (lesion-containing 
strand) of the PCR products of the progeny of the competitor genome and the control or 
lesion-carrying genome, where 10mer TT represents the [5′-32P]-labeled standard ODNs 
5′-GGCTTGCTAT-3′. 
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Figure 2-14. Native PAGE (30%) for monitoring the bypass efficiencies and mutation 
frequencies of alkylphosphotriester in triple knockout (TKO) AB1157 cells without SOS 
induction (WT). (a) Selective labelling of original lesion-containing strand via sequential 
restriction digestion. ‘SAP’ and ‘PNK’ represent shrimp alkaline phosphatase and T4 
polynucleotide kinase, respectively. (b) Gel image showing the 13-mer and 10-mer 
products released from the top-strand (lesion-containing strand) of the PCR products of 
the progeny of the competitor genome and the control or lesion-carrying genome, where 
where 10mer TT, 10mer GC, and 10mer GT represent the [5′-32P]-labeled standard ODNs 
5′-GGCMNGCTAT-3′, with ‘MN’ being TT, GC and GT, respectively. 
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Figure 2-15. Higher-resolution “ultra-zoom scan” ESI-MS of the restriction fragments 
for the PCR products from the replication of Sp- and Rp-methyl phosphotriester-bearing 
single-stranded M13 genomes in SOS-induced wild-type AB1157 cells. Displayed are the 
[M-3H]3- ions for the lesion-containing top strand products. All the mutagenic products 
were further confirmed by MS/MS analyses, and representative MS/MS results for the 
restriction fragments corresponding to replication products for Sp-methyl phosphotriester 
are shown in Figure 2-16. 
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Figure 2-16. LC-MS and MS/MS for the identification of restriction fragments of PCR 
products. MS/MS for the [M – 3H]3- ions of (a) 10 mer TT (non-mutagenic product), (b) 
10 mer GT (TT→GT mutation), and 10 mer GC (TT→GC mutation). 
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Figure 2-17. Bypass efficiencies of alkyl phosphotriester lesions (a) and mutation 
frequencies of the Sp methyl phosphotriester lesion (b) in AB1157 E. coli strains that are 
proficient or deficient in SOS-induced DNA polymerases, Pol II, Pol IV, Pol V, alone or all 
three in combination. The data represent the means and standard deviations of results from 
three independent replication experiments. *, 0.01 < p < 0.05. The p values were calculated 
by using an unpaired two-tailed t-test and referred to comparisons with the data obtained 
for control cells. 
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Figure 2-18. Ada protein promotes the replicative bypass of the Sp-Me-PTE, but not the 
Rp-Me-PTE or the Sp-/Rp-Et-PTE lesion, and Ada is required for the mutations induced by 
Sp-Me-PTE. (a) Selective labelling of original lesion-containing strand and its 
complementary strand via sequential restriction digestion. ‘SAP’ and ‘PNK’ represent 
shrimp alkaline phosphatase and T4 polynucleotide kinase, respectively. (b) Gel image 
showing 13 mer (from the competitor genome) and 10 mer (from the control or lesion-
containing genome) digestion products formed from the strand initially containing the 
lesion, where 10 mer TT, 10 mer GC and 10 mer GT designate [5-32P]-labeled standard 
ODNs 5-GGCMNGCTAT-3, with MN being TT, GC and GT, respectively. (c) The bypass 
efficiencies of the two diastereomers of Me- and Et-PTE lesions in E. coli cells that are 
proficient in DNA repair or deficient in both Ada and Ogt (ΔAda, ΔOgt). The data represent 
the means and standard deviations of results from three independent replication 
experiments. ***, p <0.001. The p values were calculated by using an unpaired two-tailed 
t-test and referred to comparisons with the data obtained for control cells. 
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Figure 2-19. Gel image showing the time-dependent CRAB assay of 13-mer and 10-mer 
products released from the top-strand (lesion-containing strand) of the PCR products of 
the progeny of the competitor genome and the control or lesion-carrying genome. (a) 
Selective labelling of original lesion-containing strand via sequential restriction digestion. 
‘SAP’ and ‘PNK’ represent shrimp alkaline phosphatase and T4 polynucleotide kinase, 
respectively. (b) Gel image showing the 13-mer and 10-mer products released from the 
top-strand (lesion-containing strand) of the PCR products of the progeny of the 
competitor genome and the control or lesion-carrying genome, where 10mer TT represent 
the [5′-32P]-labeled standard ODNs 5′-GGCMNGCTAT-3′, with ‘MN’ being TT, 
respectively. (c) Bypass efficiencies of alkyl phosphotriester lesions in wild-type AB1157 
Escherichia coli strains. The data represent the means and standard deviations of results 
from three independent replication experiments. **, 0.001 < p < 0.01. The p values were 
calculated by using an unpaired two-tailed t-test and referred to comparisons with the 
data obtained for control cells. 
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CHAPTER 3 
 
Ada- and Sequence Context-dependent Mutagenesis of Alkyl Phosphotriester 
Lesions in Escherichia coli cells 
 
INTRODUCTION 
The specific sequence of DNA within an organism imparts the genetic code for all domains 
of life; however, this code is susceptible to alterations due to limited chemical stability of 
DNA (1). As a result, the genetic integrity of DNA can be compromised by endogenous 
metabolites and exogenous chemicals, resulting in different types of damage (1,2).  
Alkylation is a major type of DNA damage (3), and the cytotoxic effects of DNA 
alkylation adducts are manifested by the fact that DNA alkylation constitutes the central 
mechanism of action for many prescribed chemotherapeutic agents (2). Nucleobase 
modifications have been the major focus of DNA alkylation studies (3), though efficient 
formation of alkyl phosphotriesters (alkyl-PTEs) have also been demonstrated (4). The 
latter lesions are induced when alkylating agents react with one of the two non-carbon-
bonded oxygen atoms and, based on which of these oxygen atoms is attacked, alkyl-PTEs 
can form in Sp or Rp configuration (4). It was also shown that chronic exposure of rats to 
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4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a major tobacco-specific N-
nitrosamine, through drinking water induces the formation of Me-PTE lesions in lung 
tissues (5). 
There have been some studies about the repair and biological consequences of alkyl-
PTEs (4). Since the addition of an alkyl group to the backbone phosphate neutralizes its 
negative charge, the presence of alkyl-PTE lesions in DNA may perturb its interactions 
with proteins. For instance, a mixture of Sp- and Rp-ethyl-PTE inhibits in vitro primer 
extension catalyzed by T4 DNA polymerase and E. coli polymerase I (6). Isopropyl-PTE 
was also found to inhibit the unwinding of duplex DNA mediated by SF2 DNA helicases 
(6). Our previous study showed that the two diastereomers of alkyl-PTEs exhibited 
different replication bypass efficiencies in E. coli cells, where replication across Sp-Me-
PTE at TT dinucleotide site is mutagenic and the mutagenicity of the lesion requires the 
presence of Ada protein (7).  
Previous research indicated that the frequencies for the formation of alkyl-PTEs are 
influenced by flanking sequences. For instance, Guichard et al. (8) employed N-
nitrosodiethylamine (NDEA) to treat three strains of mice, detected the levels of Et-PTE 
products by 32P-postlabeling, and observed higher frequencies of Et-PTE lesions with the 
5-flanking nucleoside being a thymidine or 2-deoxyguanosine compared to a 2-
deoxyadenosine or 2-deoxycytidine. Likewise, the relative frequencies of 5-nucleobases 
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at PTE sites exhibit non-random distribution in calf thymus DNA and liver DNA of 
BALB/c mice treated with diethyl sulfate (9). LC-MS/MS results also revealed the effects 
of flanking sequences on the levels of Me-PTE lesions induced in lung tissues of rats 
treated with NNK and its metabolite, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol 
(NNAL) (5). Several models were proposed to rationalize the sequence-dependent 
accumulation of alkyl-PTE lesions: 1) Other than the non-carbon-bound oxygen atoms on 
backbone phosphate groups, each nucleobase possesses unique nucleophiles, which exhibit 
different reactivities toward alkylating agents; 2) the alkylating agents’ electrophilicity may 
also influence the non-random distribution of alkyl-PTE lesions, where highly reactive 
alkylating agents may yield a more random distribution (4); or 3) the repair efficiencies for 
alkyl-PTEs may vary with flanking base sequences. However, not much is known about 
how the flanking base sequence context modulates the biological consequences of alkyl-
PTEs.  
Here, we employed a shuttle vector-based method, in conjunction with LC-MS 
(10,11), to analyze how the flanking sequences of methyl- and n-butyl-PTE lesions 
influence the fidelity and efficiency of DNA replication in E. coli cells, and how replication 
past alkyl-PTEs is modulated by Ada protein and translesion synthesis DNA polymerases. 
Considering that we have previously investigated the TT sequence, here we examined the 
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Me- and nBu-PTE lesions in both Sp and Rp configurations and in six different 
combinations of flanking sequences (TX and XT, with ‘X’ being A, C or G) (Figure 3-1). 
MATERIALS AND METHODS 
Materials  
Chemicals were, unless otherwise specified, from Sigma-Aldrich (St Louis, MO, USA) or 
Thermo Fisher Scientific (Pittsburg, PA, USA). Common reagents for solid-phase DNA 
synthesis were from Glen Research (Sterling, VA, USA) and all unmodified 
oligodeoxyribonucleotides (ODNs) were from Integrated DNA Technologies (Coralville, 
IA, USA). 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) was from Oakwood Products Inc. 
(West Columbia, SC, USA), and [-32P] ATP was obtained from Perkin Elmer (Piscataway, 
NJ, USA). All enzymes were purchased from New England Biolabs (Ipswich, MA, USA).    
M13mp7 (L2) plasmid and wild-type AB1157 E. coli strains were kindly provided by 
Prof. John M. Essigmann (13,14). Polymerase-deficient AB1157 E. coli strain [Δpol 
B1::spec ΔdinB ΔumuC::kan (Pol II, Pol IV, Pol V-triple knockout)] was generously 
provided by Prof. Graham C. Walker (13). Ada-deficient AB1157 E. coli strain was 
generated following published procedures (15).  
 
76 
 
Chemical syntheses 
The 5′-DMTr-protected nucleoside derivatives were synthesized according to the published 
procedure (Scheme 3-1) (12-15). For methoxyphosphine synthesis (compound 10, X=Me), 
compound 9 (200 mg, 0.75 mmol) was dissolved in 10 ml of diethyl ether in an ice bath 
under argon protection. Methanol (114 μl, 2.8 mmol) and triethylamine (4 ml, 2.8 mmol) 
were subsequently added to the mixture. After stirring at room temperature for 12 h, 10 ml 
of petroleum ether was added, and the precipitate was removed by filtration. The 
supernatant was concentrated to yield methoxyphosphine. For n-butoxyphosphine 
synthesis (compound 10, X=nBu), n-butanol (82 μl, 0.9 mmol) was gradually added to a 
mixture of compound 9 (200 mg, 0.75 mmol) and triethylamine (130 μl, 0.9 mmol) in 
tetrahydrofuran (2 ml) under an argon atmosphere in an ice water bath. The mixture was 
stirred at room temperature for 1 h and filtered. The filtrate was concentrated, redissolved 
in 5 ml pentane and filtered again. The solvent in the filtrate was removed under vacuum 
to yield n-butoxyphosphine. 
For the preparation of compounds 11a1-d1, compound 10 (1 eq. X=Me) and 
diisopropylamine hydrotetrazolide (1 eq.) was added to a round bottom flask containing a 
solution of compound 8a-d in 1 ml anhydrous dichloromethane. The mixture was stirred 
at room temperature under argon protection for 1 h. The solvent was removed, and the 
mixture was separated using flash column chromatography with a mixture of hexane, ethyl 
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acetate and triethylamine to yield the phosphoramidite building block 11a1-d1. For the 
preparation of compounds 11a2-d2, a solution of compound 8a-d (60 mg) and tetrazole (1 
eq.) in 1 ml acetonitrile was added to a solution of compound 10 (1 eq. X=nBu) in 
dichloromethane (1 ml) under argon protection. The reaction mixture was stirred for 5 h, 
concentrated by rotary evaporation, and then purified by flash column chromatography to 
yield building block 11a2-d2. The NMR spectra for these compounds are shown in Figures 
3-2 to 3-5. 
ODN synthesis  
A Beckman Oligo 1000M DNA synthesizer (Fullerton, CA) was used to synthesize the 12-
mer lesion-containing ODNs, 5-ATGGCX(Y)TGCTAT-3 and 5-ATGGCT(Y)XGCTAT-
3 (‘X’ represents A, C or G; ‘Y’ represents a Me or nBu group) at 1 μmol scale. The 
synthesized phosphoramidite building block was dissolved in anhydrous acetonitrile at a 
concentration of 67 mM. Incorporation of unmodified nucleotides was conducted by using 
commercially available ultramild phosphoramidite building blocks (Glen Research Inc., 
Sterling, VA, USA) following standard protocols. Synthesized ODNs were cleaved and 
deprotected from controlled pore glass with concentrated ammonium hydroxide at room 
temperature for 55 min. After solvent removal using a Speed-Vac, the solid residues were 
dissolved in water and purified by high-performance liquid chromatography (HPLC). 
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HPLC   
HPLC separation was conducted on an Agilent 1100 system with a Synergi Fusion-RP 
column (10 × 150 mm, 4 μm in particle size and 80 Å in pore size; Phenomenex Inc., 
Torrance, CA, USA). Triethylammonium acetate (TEAA) solution (50 mM, pH 6.8), and 
a mixture of 50 mM TEAA and acetonitrile (70:30, v/v) were employed as mobile phases 
A and B, respectively. The gradient profile was 5-30% B in 5 min and 30-60% B in 70 min, 
and the flow rate was 0.8 ml/min. The HPLC traces for the purification of the 12-mer 
lesion-containing ODNs are shown in Figure 3-6 and their electrospray ionization-mass 
spectra (ESI-MS) and tandem MS (MS/MS) are provided in Figures 3-7 to 3-18. 
Construction of single-stranded lesion-containing and lesion-free competitor M13 
genomes   
The 12-mer lesion-containing ODNs were 5-phosphorylated and ligated with a 10-mer 
ODN (5-AGTGGAAGAC-3) to yield 22-mer lesion-containing ODNs, and the ensuing 
ligation products were purified by denaturing polyacrylamide gel electrophoresis (PAGE).  
The single-stranded lesion-containing and lesion-free competitor M13 genomes were 
prepared following published procedures (12). Briefly, 20 pmol of M13mp7 (L2) plasmid 
was digested with 40 U EcoRI-HF at 25 °C for 8 h to linearize the vector. Two scaffolds, 
5-CTTCCACTCACTGAATCATGGTCATAGCTTTC-3 and 5-
AAAACGACGGCCAGTGAATTATAGC-3 (25 pmol each), were subsequently annealed 
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with the linearized vector. A phosphorylated 22-mer lesion-containing or lesion-free 
control ODN, or a 25-mer competitor ODNs, was then added to the mixture and incubated 
with scaffold ODNs and T4 DNA ligase at 16 °C for 8 h. Unligated linear vector and ODNs 
were removed by the exonuclease activity of T4 DNA polymerase (22.5 U, 16 °C for 2 h). 
The resulting plasmids were purified using Cycle Pure Kit (Omega), and the purified 
lesion-containing and lesion-free control plasmids were subsequently normalized against 
the competitor plasmid (12). 
Preparation of Ada-deficient AB1157 E. coli strain  
P1 transduction was employed to obtain the Ada-deficient E. coli strain (Δada::kan) in 
AB1157 background (13). Genotype of the ensuing deficient strain was confirmed by 
antibiotic resistance and polymerase chain reaction (PCR) followed by sequencing. 
Transfection of M13 genomes into E. coli cells   
The lesion-free control or lesion-containing plasmids were mixed with the competitor 
plasmid at a 1:1 molar ratio. The mixtures were transfected into electrocompetent wild-
type AB1157 E. coli strains as well as the isogenic cells deficient in Ada, or all three SOS-
induced DNA polymerases (i.e. Pol II, Pol IV and Pol V) (11). The transfected E. coli cells 
were cultured at 37 °C for 5.5 h and the M13 phage was isolated from the supernatant by 
centrifugation at 13200 r.p.m. for 5 min. The purified M13 phage was transfected into 
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SCS110 E. coli cells for amplification, followed by extraction with QIAprep Spin M13 kit 
(Qiagen) to obtain M13 ssDNA template for PCR amplification.  
Quantification of bypass efficiency by the competitive replication and adduct bypass 
(CRAB) assay   
We utilized a modified version of the competitive replication and adduct bypass (CRAB) 
assay to assess the bypass efficiency of alkyl-PTE lesions in E. coli cells (10-12,14). The 
interested regions in the M13 ssDNA templates were amplified by PCR with the use of 
Phusion high-fidelity DNA polymerase. The primers were 5-
YCAGCTATGACCATGATTCAGTGAGTGGA-3 and 5-
YTCGGTGCGGGCCTCTTCGCTATTAC-3, where ‘Y’ represents a 5-amino modifier 
conjugated to the 5-phosphate group of ODNs, i.e., H2N(CH2)6-. The PCR amplification 
started from 98 °C for 30 s, followed by 35 cycles of amplification, with each cycle 
consisting of 98 °C for 10 s, 65 °C for 30 s and 72 °C for 15 s, and then with a final 
extension at 72 °C for 5 min, ending at 4 °C. The PCR products were purified by Cycle 
Pure kit (Omega).  
The PCR products (100 ng) were digested with BbsI-HF restriction endonuclease (10 
U) and recombinant shrimp alkaline phosphatase (rSAP, 10 U) in 10 μl 1× CutSmart buffer 
(New England Biolabs) at 37 °C for 25 min, followed by deactivation of rSAP at 80 °C for 
10 min. To the above mixture were added 5 mM dithiothreitol (DTT), 1.66 pmol [γ-32P]ATP, 
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10 U T4 polynucleotide kinase (T4 PNK), CutSmart buffer and water to give a total volume 
of 15 μl. The mixture was incubated at 37 °C for 30 min, and T4 PNK was then deactivated 
by heating the solution at 70 °C for 10 min. The resulting mixture was further digested with 
10 U MluCI at 37 °C for 25 min and subsequently quenched by adding 15 μl formamide 
gel-loading buffer containing xylene cyanol FF and bromophenol blue dyes. The 
radiolabeled digestion mixtures were resolved using a 30% native polyacrylamide gel (19:1) 
and the intensities for the radiolabeled gel bands were measured by using a Typhoon 9410 
imager. 
The aforementioned digestion procedures yield a 10-mer duplex: 5-
p*GGCMNGCTAT-3/5-AATTATAGCY-3 for full-length replication products, with ‘M’ 
and ‘N’ being the nucleobases at the dinucleotides initially flanking the alkyl-PTE lesions, 
‘Y’ being the complementary base of ‘N’ in the opposite strand, and p* being the 
radiolabeled phosphate. The bypass efficiency was calculated by: Bypass efficiency (%) = 
(lesion signal/competitor signal)/ (control signal/competitor signal) × 100%. 
Identification and quantification of mutation frequencies by restriction endonuclease 
and mass spectrometry (REAMS) assay 
Approximately 3 μg PCR products in 250 μl of 1× CutSmart buffer was mixed with 50 U 
BbsI-HF, 20 U rSAP, and incubated at 37 °C for 2 h, followed by deactivation of rSAP at 
80 °C for 20 min. MluCI (20 U) was subsequently added to the mixture and the digestion 
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was continued at 37 °C for 1 h. The resulting mixture was extracted once with 
phenol/chloroform/isoamyl alcohol (25:24:1, v/v) and the aqueous phase was evaporated, 
desalted by Waters Oasis HLB extraction cartridges (Milford, MA), and redissolved in 10 
μl water. A 5-μl aliquot was analyzed by LC-MS/MS on an LTQ linear ion trap mass 
spectrometer (Thermo Electron, San Jose, CA, USA) with an Agilent Zorbax SB-C18 
column (0.5 × 150 mm, 5 μm in particle size). The gradient was 5 min of 5–20% methanol 
followed by 35 min of 20–50% methanol in 400 mM HFIP (pH was adjusted to 7.0 with 
triethylamine). The temperature for the ion-transfer tube was 300 °C, and the mass 
spectrometer was set up for acquiring the higher-resolution ‘ultra-zoom scan’ MS and full-
scan MS/MS for the [M-3H]3- ions of 10 mer ODNs, d(GGCMNGCTAT), with ‘M’ and 
‘N’ being A, T, C and G. 
Plasmid construction and protein purification.  
E. coli ada gene was amplified from AB1157 strains with primers containing BamHI and 
XhoI restriction recognition sites and inserted into the pGEX-4T1 vector, which was 
generously provided by Prof. Chuan He. The sequences of primers are listed in Table 3-1. 
    Recombinant Ada protein was obtained by inducing transformed Rosetta (DE3) pLysS 
E. coli cells with isopropyl 1-thio-β-D-galactopyranoside (IPTG) to a final concentration 
of 0.5 mM when DE3 culture reached OD600 ≈ 0.55, followed by culture at 37 °C for 4 h. 
The recombinant protein was extracted using Pierce Glutathione Agarose (Thermos) and 
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then eluted with a reduced glutathione solution (3 mg/ml), followed by concentration using 
Microcon ultracentrifugal filters (Millipore). 
Electrophoresis mobility shift assay (EMSA)  
Single-stranded ODNs were radiolabeled on the 5′ termini at 37 °C for 30 min in a mixture 
containing 10 U T4 PNK and 1.66 pmol [γ-32P]ATP in 10 μl PNK buffer, followed by 
deactivation of the enzyme by heating at 70 °C for 20 min. For duplex DNA, the 
radiolabeled ODNs were annealed with the corresponding complementary strands at a 1:1 
molar ratio. 
The binding experiments were conducted using solutions containing 0-1.5 μM Ada 
protein, 1 nM of labeled 22 mer lesion-containing or lesion-free DNA in a binding buffer 
[10 mM Tris (pH 7.5), 1 mM EDTA, 0.1 M KCl, 0.1 mM DTT, 5% glycerol and 10 μg/ml 
BSA]. The mixtures were incubated at room temperature for 1 h, followed by separation 
on a 10% 29:1 polyacrylamide gel in TAE buffer (40 mM Tris, 2.5 mM EDTA, pH 7.8) at 
4 °C for 45 min.  
RESULTS 
The aim of the present study was to gain a comprehensive understanding about the impact 
flanking base sequences have on DNA replication past alkyl-PTE lesions in E. coli, and to 
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examine the roles of Ada protein and TLS polymerases in modulating the replicative bypass 
of these lesions.  
We synthesized 12-mer ODNs containing a site-specifically inserted alkyl-PTE lesion 
in different sequence contexts following our recently published procedures (7), with the 
modification that the exocyclic amino groups of adenine, cytosine and guanine bases in the 
phosphoramidite building blocks were protected (see Materials and Methods). The 
synthesized ODNs were purified by using HPLC (Figure 3-6). Because the Sp and Rp 
diastereomers of the T(Me)C- and T(nBu)A-containing ODNs cannot be resolved from 
each other by HPLC, a mixture of the two diastereomers were utilized for these two ODNs 
in the subsequent experiments. We characterized the ODNs using ESI-MS and MS/MS and 
the results confirmed the expected site of alkyl-PTE incorporation and the sequences of the 
modified ODNs (Figures 3-7 to 3-18). 
We employed a previously reported shuttle vector method to assess the bypass 
efficiencies and mutation frequencies of the alkyl-PTE lesions (12). The lesion-containing 
ODNs were ligated into single-stranded M13 phage. After replication, progeny recovery, 
PCR amplification and restriction enzyme digestion, the released ODNs were analyzed by 
native PAGE and LC-MS/MS to identify the replication products (Figures 3-19 to 3-33). 
As shown in Figure 3-19a, we employed two restriction enzymes, BbsI and MluCI, to digest 
the PCR products of the progeny genome, resulting in the liberation of the initial damage-
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containing region as 10 mer ODNs for the lesion-containing or control genome, or a 13 
mer ODN for the corresponding region in the competitor genome. By switching the order 
of digestion of the two restriction enzymes, we selectively radiolabel the 5-terminus of 
either the original lesion-situated strand (p*GGCMNGCTAT) or the opposite strand 
(p*AATTATAGCY).  
Replication across the alkyl-PTEs may yield up to 16 potential products (i.e. with the 
four natural nucleotides being incorporated at the two nucleosides flanking the PTE site), 
which could not be completely resolved from one another by PAGE analysis. Thus, we 
employed a restriction endonuclease and mass spectrometry (REAMS) assay (10) to 
identify the mutagenic products and to quantify the mutation frequency. In this vein, the 
aforementioned digestion products were subjected to LC-MS and MS/MS analyses, where 
we monitored the fragmentation of the [M-3H]3- ions. The mutation frequencies were 
quantified by the calibrated ratios of peaks found in the selected-ion chromatograms (SICs) 
for the mutagenic and non-mutagenic products (Figures 3-22, 3-23 and 3-29b). Intriguingly, 
we found that the replication products of the Sp-Me-PTEs at the three XT sites (‘X’ = A, C 
or G) are largely independent of the neighboring 5 nucleosides, with ~85-90% and ~5-10% 
of products carrying AT and TG at bases flanking the initial damage site, respectively, 
though replication across C(Me)T also yields 7% of non-mutagenic replication products 
(Figures 3-20, 3-21). Additionally, none of the Rp diastereomers of the Me-PTEs in the TX 
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sequences, neither diastereomer of Me-PTEs in the TX sequences, and none of the nBu-
PTEs in the TX or XT sequence are mutagenic (Figures 3-20, 3-24, 3-27 and 3-28).  
The bypass efficiencies of the Me-PTE lesions were quantified by comparing the 
relative intensity of signal for the 10-mer products from the lesion-containing or control 
genome, to that of the 13-mer replication product from the competitor genome; this value 
was adjusted based on the molar ratios of lesion/competitor and control/competitor 
genomes used for the transfection (Figure 3-29a). For Me-PTEs, none of the Sp-PTEs at 
the three XT sites were strong impediments to DNA replication, though the corresponding 
Rp diastereomers significantly blocked DNA replication. Additionally, the blockage effects 
were more pronounced when the flanking 5-nucleobase was a purine (adenine and 
guanine). Meanwhile, all TX-PTEs elicited moderate blockage effects on DNA replication.  
We also examined whether SOS-induced DNA polymerases (Pol II, Pol IV and Pol V) 
promote the replicative bypass of different Me-PTEs. Our results showed that, similar to 
the results obtained for the alkyl-PTE lesions at TT site (7), genetic depletion of all three 
SOS-induced DNA polymerases did not exert any apparent effects on the replication bypass 
efficiencies for the Me-PTE lesions. For nBu-PTEs, we found that none of the Sp-PTEs at 
XT sites significantly impede DNA replication in E. coli cells, whereas the Rp diastereomer 
in the XT sequence and both diastereomers of nBu-PTEs in the TX sequence confer 
moderate blockage effects (Figure 3-29c). 
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Considering our previous observation that Ada protein can influence the mutagenicity 
and cytotoxicity of Sp-Me-PTE at TT dinucleoside site (7), we next asked how Ada protein 
affects the replication bypass efficiencies and mutation patterns of Sp-Me-PTEs in different 
flanking base sequences (Figures 3-30 to 3-33). We found that removal of the ada gene 
resulted in a moderate decline in bypass efficiencies for the Sp-Me-PTEs in all three XT 
sequences, and a complete abrogation of mutations. However, depletion of ada gene did 
not elicit significant effects on the replication efficiencies or mutations arising from Sp-Me-
PTEs in any of the three TX sequences. 
The above strong flanking sequence- and Ada-dependent mutagenesis of Sp-Me-PTE 
lesions prompted us to examine the binding capabilities of purified Ada protein to single- 
and double-stranded DNA containing a Sp-Me-PTE in two flanking base sequences (AT 
and TA) (Figure 3-34). Our results from electrophoretic mobility shift assay (EMSA) 
showed that Ada protein binds more strongly to single-stranded Sp-A(Me)T-containing 
ODN than its unmethylated counterpart, whereas Sp-T(Me)A-containing ODN did not 
display significant difference in binding toward Ada relative to the corresponding TA-
containing ODN. In this vein, Ada protein also exhibits stronger binding to single-stranded 
lesion-free ODN with an AT sequence relative to the corresponding ODN with a TA 
sequence, though the binding affinities of the protein to duplex DNA are independent of 
whether the DNA carries a Me-PTE. 
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DISCUSSION 
We previously investigated how size and stereochemistry of the alkyl-PTEs at TT site 
influence DNA replication in E. coli (7). Here, we systematically investigated how 
compositions of the flanking nucleobases of the alkyl-PTE lesions affect DNA replication. 
We found that, for Me-PTEs in XT sequences (X = A, C, G), some of the characteristics 
were the same as what we found for the replicative bypass of T(Me)T (7). First, we 
demonstrated that neither the replication bypass efficiency nor the mutation frequency of 
Me-PTEs was impacted by genetic depletion of all three SOS-induced DNA polymerases. 
Second, we revealed that none of Sp-Me-PTEs in the three XT sequences suppress DNA 
replication in E. coli cells, whereas the Rp-Me-PTEs in the three sequence contexts exhibit 
significant replication blockage effects. Third, we show that Sp-Me-PTEs at XT sites are 
mutagenic and Ada protein is indispensable for the mutagenic bypass. In this vein, removal 
of Ada protein also resulted in a decrease in bypass efficiencies for the Sp-Me-PTEs in the 
three XT sequences. 
We also uncover some unique features regarding replication past alkyl-PTEs with 
different flanking base sequences. Strikingly, we found that the distribution of replication 
products for Sp-Me-PTEs in the three XT sequences (X = A, C or G) was largely 
independent of the 5-neighboring nucleobase being an A, C, or G, where approximately 
85-90% and 5-10% of the replication products for the Sp-Me-PTEs at XT sties were AT and 
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TG, respectively. In this context, it is worth noting that Sp-Me-PTE at TT site induced 50% 
TT→GT and 15% TT→GC mutations, and Ada protein is also essential for the induction 
of these mutations (Figure 3-33) (7).  
Ada was reported to remove the methyl group from Sp-Me-PTEs, where Cys38 on N-
terminal domain of the protein interacts with the methyl group on the DNA backbone 
(15,16). A previous structural study showed that the methylated N-terminal domain of Ada 
protein preferentially recognizes A/T in the Ada box (15,17). In this recognition, Arg45 
participates in hydrogen bonding interactions with thymine residues in both strands, and 
the binding with Arg45 is sterically incompatible with a G positioned in the last two bases 
of the Ada box (15,17), which is consistent with the sequence specificity observed for 
replication past alkyl-PTEs.  
In contrast to what we found for Me-PTEs at XT sites (X = A, C, G, T), replication 
across the Me-PTEs at TX sites (X=A, C and G) was accurate. In addition, genetic ablation 
of Ada did not alter the efficiency or fidelity of replication across any of the Me-PTEs at 
TX site. We also examined the replication past nBu-PTEs and found that the trends in 
bypass efficiency was similar to what we found for Me-PTEs (Figure 3-29c); however, 
none of nBu-PTEs were mutagenic.  
The results from our replication studies are supportive of a model where Ada protein 
binds to Sp-Me-PTE lesions formed at XT dinucleotide sites, and this binding is maintained 
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during the replicative bypass of these lesions in single-stranded DNA. Moreover, this 
interaction with Ada protein also assists the replicative bypass of these lesions in E. coli 
cells. The lack of apparent dependence of profiles of replication products for the Sp-Me-
PTE lesion in the three XT sequences (X = A, C or G) on the identities of the 5-flanking 
nucleobases strongly suggests their lack of recognition by DNA polymerases during 
nucleotide incorporation at the site. These results, together with the previous observation 
that an arginine residue in REV1 could direct the incorporation of dCMP through direct 
hydrogen bonding interaction with the nucleobase in the incoming nucleotide (20), suggest 
that some amino acid(s) in the Ada protein may direct nucleotide incorporation when 
replicating past the 5 flanking nucleotide of the Me-PTE lesions. Consistent with this 
notion, we found that single-stranded (ss) DNA with an Sp-A(Me)T displayed augmented 
binding relative to the corresponding ssDNA with an Sp-T(Me)A, suggesting that the 
flanking 3′-T enhances the interaction between Sp-Me-PTEs and Ada protein.  
Harper et. al. (21) analyzed the mutations induced by N-methyl-N-nitro-N-
nitrosoguanidine in sixteen different strains of E. coli, and they found that 96.6% of the 
4099 detected mutations were G→A transition mutation, which were attributed to O6-
MedG (14,22). Our results, however, suggest that the G→A mutation may also arise, in 
part, from Sp-Me-PTE formed at GT site.  
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In summary, the results from our shuttle vector-based replication study showed that 
flanking base sequences play important roles in DNA replication across Me- and nBu-PTE 
lesions. Sp-Me- PTEs and Sp-nBu-PTEs at XT sites (X = A, C, G) were not strong 
impediments to DNA replication, whereas their Rp counterparts exhibited blockage effects. 
Meanwhile, Me- and nBu-PTEs at TX sites moderately block DNA replication in E. coli. 
Furthermore, the Sp-Me-PTEs at XT sites resulted in 85-90% XT→AT and 5-10% XT→
TG mutations, which require the presence of Ada protein. However, this phenomenon was 
not observed for Rp-Me-PTEs at TX sites, which is consistent with the notion that Ada 
protein does not recognize Rp-Me-PTEs. There are two established functions for Ada 
protein, i.e. removal of the methyl group from Sp-Me-PTE or O6-MedG, and transcriptional 
activation of ada, alkA, alkB and aidB genes (3,18,19); both functions are mediated by the 
N-terminal domain of Ada (15). Our work suggests that, aside from these two well-
characterized functions, Ada may assume other important functions in cells. Along this line, 
it will be important to examine whether Me-PTE lesions are endogenous modifications and 
whether they assume regulatory roles in E. coli cells. In addition, future studies about how 
alkyl-PTE lesions influence DNA replication in mammalian cells will provide additional 
insights into the biological impacts of this unique class of DNA damage.  
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FIGURES AND SCHEMES 
 
Figure 3-1. Sp and Rp diastereomers of alkyl phosphotriester residues in DNA (X=Me or 
nBu). 
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Scheme 3-1. Syntheses of alkyl phosphoramidite building blocks. Reagents and 
conditions: (a) acetic anhydride, N,N-dimethylformamide, R. T. , 24 h; (b) 4,4-
dimethoxytrityl chloride, 4-dimethylaminopyridine, pyridine, R. T. , 10 h; (c) 
trimethylsilyl chloride, pyridine, R.T., 1 h; (d) phenoxyacetyl chloride, R.T., 2 h; (e) 
saturated NaHCO3 solution, R.T., 5 h; (f) 4-isopropylphenoxyacetyl chloride, 4-
dimethylaminopyridine, R.T., 2 h; (g) X=Me: Methanol, triethylamine, diethyl ether, ice 
bath, 14 h; X=nBu: n-butanol, triethylamine, tetrahydrofuran, R. T. , 1 h; (h) X=Me: 
diisopropylamine hydrotetrazolide, dichloromethane, R. T. , 1 h; X=nBu: tetrazole, 
acetonitrile, dichloromethane, R.T., 5 h. 
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Figure 3-2. The 1H NMR (400 MHz, CDCl3, 25°C, top) and 31P NMR (80 MHz, CDCl3, 
25ºC, bottom) spectra of N4-AcdC-methylphosphoramidite. 
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Figure 3-3. The 1H NMR (400 MHz, CDCl3, 25°C, top) and 31P NMR (80 MHz, CDCl3, 
25ºC, bottom) spectra of N6-PacdA-methylphosphoramidite. 
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Figure 3-4. The 1H NMR (400 MHz, CDCl3, 25°C, top) and 31P NMR (80 MHz, CDCl3, 
25ºC, bottom) spectra of N2-iPrPacdG-methylphosphoramidite. 
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Figure 3-5. The 1H NMR (400 MHz, CDCl3, 25°C, top) and 31P NMR (80 MHz, CDCl3, 
25ºC, bottom) spectra of N4-AcdC-n-butylphosphoramidite. 
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Figure 3-6. HPLC traces for the separations of the synthesized 12mer 
methylphosphotriester-bearing ODNs: (a) T(Me)A; (b) T(Me)C; (c) T(Me)G; (d) 
A(Me)T; (e) C(Me)T; (f) G(Me)T; (g) T(nBu)A; (h) T(nBu)C; (i) T(nBu)G; (j) A(nBu)T; 
(k) C(nBu)T; (l) G(nBu)T. 
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Figure 3-7. ESI-MS & MS/MS characterizations of d(ATGGCT(MeSp)AGCTAT): (a) 
Negative-ion ESI-MS; (b) the product-ion spectrum of the [M-3H]3- ion (m/z 1223.7). 
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Figure 3-8. ESI-MS & MS/MS characterizations of d(ATGGCT(Me)CGCTAT): (a) 
Negative-ion ESI-MS; (b) the product-ion spectrum of the [M-3H]3- ion (m/z 1215.6). 
700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
m/z
0
50
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
(%
)
729.2
1823.5
911.6
1215.6
[M-2H]2-
[M-3H]3-
[M-4H]4-
[M-5H]5-
600 800 1000 1200 1400 1600 1800 2000
m/z
0
50
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
(%
)
1137.8
1170.6
1225.9
1081.4
1390.4
1043.3
989.4
1298.5938.3714.3
1594.8
1556.2
A T G G C T (Me) C G C T A T
w
5
w5
a5-C
1372.4
a
5
-C
1227.1
w
4
w4
a
4
-G
a4-G
w
3
w3
a
3
-G
a3-G [a11-A]
2-
a
1
1
-A
w
9
w9
2-
a
9
-C
[a9-C]
2-
w
8
w8
2-
1133.9
a
8
-G
[a8-G]
2- w
7
w7
2-
a
7
-C
[a7-C]
2-
w
1
1
w11
3-
a
b
[M-Ade]3-1165.2
[M-Gua]3-
105 
 
 
Figure 3-9. ESI-MS & MS/MS characterizations of d(ATGGCT(MeSp)GGCTAT): (a) 
Negative-ion ESI-MS; (b) the product-ion spectrum of the [M-3H]3- ion (m/z 1229.4). 
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Figure 3-10. ESI-MS & MS/MS characterizations of d(ATGGCA(MeSp)TGCTAT): (a) 
Negative-ion ESI-MS; (b) the product-ion spectrum of the [M-3H]3- ion (m/z 1223.6). 
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Figure 3-11. ESI-MS & MS/MS characterizations of d(ATGGCC(MeSp)TGCTAT): (a) 
Negative-ion ESI-MS; (b) the product-ion spectrum of the [M-3H]3- ion (m/z 1215.3). 
700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900 2000
m/z
0
50
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
(%
)
728.7
911.1
1215.3
1823.4
[M-2H]2-
[M-3H]3-
[M-4H]4-
[M-5H]5-
600 800 1000 1200 1400 1600 1800 2000
m/z
0
50
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
(%
)
1138.0
1390.6
1226.1
1081.5
1043.4
938.3
714.3
1298.7
1595.3
1661.8
A T G G C C (MeSp) T G C T A T
a
6
-C
a6-C
a5-C
1372.4
a
5
-C
a
4
-G
a4-G
w
3
w3
a
3
-G
a3-G
a
1
1
-A
[a11-A]
2-
w
9
w9
2-
a
9
-C
[a9-C]
2-
w
8
w8
2-
1134.0
a
8
-G
[a8-C]
2-
w
7
w7
2-
937.0
w
6
w6
2-
w
1
1
w11
3-
1165.4
[M-Gua]3-
1170.6
[M-Ade]3-
a
b
108 
 
 
Figure 3-12. ESI-MS & MS/MS characterizations of d(ATGGCG(MeSp)TGCTAT): (a) 
Negative-ion ESI-MS; (b) the product-ion spectrum of the [M-3H]3- ion (m/z 1228.6). 
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Figure 3-13. ESI-MS & MS/MS characterizations of d(ATGGCT(nBu)AGCTAT): (a) 
Negative-ion ESI-MS; (b) the product-ion spectrum of the [M-3H]3- ion (m/z 1237.6). 
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Figure 3-14. ESI-MS & MS/MS characterizations of d(ATGGCT(nBuSp)CGCTAT): (a) 
Negative-ion ESI-MS; (b) the product-ion spectrum of the [M-3H]3- ion (m/z 1229.5). 
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Figure 3-15. ESI-MS & MS/MS characterizations of d(ATGGCT(nBuSp)GGCTAT): (a) 
Negative-ion ESI-MS; (b) the product-ion spectrum of the [M-3H]3- ion (m/z 1242.7). 
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Figure 3-16. ESI-MS & MS/MS characterizations of d(ATGGCA(nBuSp)TGCTAT): (a) 
Negative-ion ESI-MS; (b) the product-ion spectrum of the [M-3H]3- ion (m/z 1237.4). 
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Figure 3-17. ESI-MS & MS/MS characterizations of d(ATGGCC(nBuSp)TGCTAT): (a) 
Negative-ion ESI-MS; (b) the product-ion spectrum of the [M-3H]3- ion (m/z 1229.9). 
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Figure 3-18. ESI-MS & MS/MS characterizations of d(ATGGCG(nBuSp)TGCTAT): (a) 
Negative-ion ESI-MS; (b) the product-ion spectrum of the [M-3H]3- ion (m/z1243.3). 
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Figure 3-19. Restriction enzyme digestion and radiolabeling, followed by native PAGE 
(30%) analysis for quantifying the bypass efficiencies of Me-PTE lesions located in 
different sequence contexts in wild-type AB1157 E. coli cells. (a) Selective labelling of the 
original lesion-containing strand and its complementary strand via sequential restriction 
digestion. ‘SAP’ and ‘PNK’ designate shrimp alkaline phosphatase and T4 polynucleotide 
kinase, respectively. ‘MN’ in the sequence denotes the site where the TX or XT 
dinucleotide flanking the Me-PTE lesions were incorporated. (b) Gel image showing the 
13 mer (competitor genome) and 10 mer (control or lesion-containing genome) digestion 
products formed from the original strand, where 10 mer AT, 10 mer CT and 10 mer TG 
designate [5-32P]-labeled standard ODNs 5-GGCMNGCTAT-3, with MN being AT, CT 
and TG, respectively. (c) Gel image showing the 13 mer (competitor genome) and 10 mer 
(control or lesion-containing genome) digestion products formed from the opposite strand, 
where 10 mer A and 10 mer C indicate the [5-32P]-labeled standard ODNs 5- 
AATTATAGCY-3, with ‘Y’ being A and C, respectively. 
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Figure 3-20. Higher-resolution “zoom scan” ESI-MS of the restriction fragments for the 
PCR products from the replication of single-stranded M13 genomes harboring a site-
specifically incorporated (a) Sp-A(Me)T, (b) Sp-C(Me)T, (c) Sp-G(Me)T, (d) Rp-A(Me)T, (e) 
Rp-C(Me)T, and (f) Rp-G(Me)T in wild-type AB1157 cells. Displayed in (a)-(f) are the [M-
3H]3- ions for the lesion-containing strand products. All the mutagenic products were 
further confirmed by MS/MS analyses, and representative MS/MS results for the restriction 
fragments corresponding to replication products for Me-PTE lesions are shown in Figures 
3-21.  
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Figure 3-21. LC-MS and MS/MS for the identification of restriction fragments of PCR 
products. MS/MS for the [M-3H]3- ions of (a) 10 mer AT, (b) 10 mer CT, (c) 10 mer TG 
and (d) 10 mer GT. 
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Figure 3-22. LC-MS/MS for monitoring the restriction fragments of interest without 
mutation or with a XT→AT and XT→TG mutations at the original guanine portion of the 
lesion [i.e. d(GGCATGCTAT) and d(GGCTGGCTAT)]. Shown in (a) and (b) and (c) are 
the SICs for the formation of indicated fragment ions (i.e. w72-, w82- and [a9-A]2-) of these 
three ODNs.  
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Figure 3-23. Calibration curves for quantification the molar ratio between (a) 10mer 
TG/10mer AT and (b) 10mer TG/10mer CT. 
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Figure 3-24. Higher-resolution “zoom scan” ESI-MS of the restriction fragments for the 
PCR products from the replication of single-stranded M13 genomes harboring a site-
specifically inserted (a) Sp-T(Me)A, (b) Sp-T(Me)G, (c) T(Me)C, (d) Rp-T(Me)A, and (e) 
Rp-T(Me)G in wild-type AB1157 cells. Displayed in (a)-(e) are the [M-3H]3- ions for the 
lesion-containing strand products. All the mutagenic products were further confirmed by 
MS/MS analyses, and representative MS/MS results for the restriction fragments 
corresponding to replication products for Me-PTE lesions are shown in Figures 3-25.  
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Figure 3-25. LC-MS and MS/MS for the identification of restriction fragments of PCR 
products. MS/MS for the [M-3H]3- ions of (a) 10 mer TA, (b) 10 mer TC, and (c) 10 mer 
TG. 
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Figure 3-26. Native PAGE (30%) for monitoring the bypass efficiencies of nBu-PTEs in 
wild-type AB1157 E. coli cells. (a) Selective labelling of original lesion-containing strand 
and its complementary strand via sequential restriction digestion. ‘SAP’ and ‘PNK’ 
represent shrimp alkaline phosphatase and T4 polynucleotide kinase, respectively. (b) Gel 
image showing the 13-mer and 10-mer products released from the top-strand (lesion-
containing strand) of the PCR products of the progeny of the competitor genome and the 
control or lesion-carrying genome, where AT, CT, GT, TA, TC and TG represent the [5′-
32P]-labeled standard ODNs 5′-GGCMNGCTAT-3′, with ‘MN’ being AT, CT, GT, TA, TC 
and TG, respectively.  
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Figure 3-27. Higher-resolution “ultrazoom scan” ESI-MS of the restriction fragments for 
the PCR products from the replication of single-stranded M13 genome harboring a site-
specifically inserted (a) Sp-A(nBu)T; (b) Sp- C(nBu)T; (c) Sp- G(nBu)T; (d) Rp- A(nBu)T; 
(e) Rp- C(nBu)T and (f) Rp- G(nBu)T in WT cells. Displayed in (a)-(f) are the [M-3H]3- 
ions for the lesion-containing strand products. All the mutagenic products were further 
confirmed by MS/MS analyses, and representative MS/MS results for the restriction 
fragments corresponding to replication products for nBu-PTE lesions are shown in 
Figures 3-21. 
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Figure 3-28. Higher-resolution “ultrazoom scan” ESI-MS of the restriction fragments for 
the PCR products from the replication of single-stranded M13 genomes harboring a site-
specifically inserted (a) T(nBu)A; (b) Sp- T(nBu)C; (c) Sp- T(nBu)G; (d) Rp- T(nBu)C and 
(e) Rp- T(nBu)G in WT cells. Displayed in (a)-(e) are the [M-3H]3- ions for the lesion-
containing strand products. All the mutagenic products were further confirmed by 
MS/MS analyses, and representative MS/MS results for the restriction fragments 
corresponding to replication products for nBu-PTE lesions are shown in Figures 3-25. 
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Figure 3-29. Bypass efficiencies of Me-PTEs (a) and nBu-PTEs (c), and mutation 
frequencies of the Sp-Me-PTE lesions (b) in AB1157 E. coli strains that are proficient in 
translesion synthesis or with all three SOS-induced DNA polymerases (Pol II, Pol IV and 
Pol V) being genetically depleted. The data represent the mean and standard deviation of 
results from three independent replication experiments. 
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Figure 3-30. Native PAGE (30%) for monitoring the bypass efficiencies of Me-PTEs in 
ada-deficient AB1157 E. coli cells. (a) Selective labelling of the original lesion-
containing strand and its complementary strand via sequential restriction digestion. ‘SAP’ 
and ‘PNK’ represent shrimp alkaline phosphatase and T4 polynucleotide kinase, 
respectively. (b) Gel image showing the 13-mer and 10-mer products released from the 
top-strand (lesion-containing strand) of the PCR products of the progeny of the 
competitor genome and the control or lesion-carrying genome, where AT, CT, GT, TA, 
TC and TG represent the [5′-32P]-labeled standard ODNs 5′-GGCMNGCTAT-3′, with 
‘MN’ being AT, CT, GT, TA, TC and TG, respectively. 
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Figure 3-31. Higher-resolution “zoom scan” ESI-MS of the restriction fragments for the 
PCR products from the replication of single-stranded M13 genomes harboring a site-
specifically inserted (a) Sp-A(Me)T, (b) Sp-C(Me)T, (c) Sp-G(Me)T, (d) Rp-A(Me)T, (e) Rp-
C(Me)T, and (f) Rp-G(Me)T in ada-deficient cells. Displayed in (a)-(f) are the [M-3H]3- 
ions for the lesion-containing strand products. All the mutagenic products were further 
confirmed by MS/MS analyses, and representative MS/MS results for the restriction 
fragments corresponding to replication products for Me-PTE lesions are shown in Figures 
3-21.  
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Figure 3-32. Higher-resolution “zoom scan” ESI-MS of the restriction fragments for the 
PCR products from the replication of single-stranded M13 genomes harboring a site-
specifically inserted (a) Sp-T(Me)A, (b) Sp-T(Me)G, (c) T(Me)C, (d) Rp-T(Me)A, and (e) 
Rp-T(Me)G in ada-deficient cells. Displayed in (a)-(e) are the [M-3H]3- ions for the lesion-
containing strand products. All the mutagenic products were further confirmed by MS/MS 
analyses, and representative MS/MS results for the restriction fragments corresponding to 
replication products for Me-PTE lesions are shown in Figures 3-25.  
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Figure 3-33. Ada protein promotes the replicative bypass of the Sp-XT-Me-PTEs and is 
required for the mutations induced by the lesions. (a) Selective labelling of original lesion-
containing strand and its complementary strand via sequential restriction digestion. ‘SAP’ 
and ‘PNK’ represent shrimp alkaline phosphatase and T4 polynucleotide kinase, 
respectively. (b) The bypass efficiencies of the Me-PTE lesions in E. coli cells that are 
proficient in or deficient in Ada (ΔAda). The data represent the mean  S.D. of results from 
three independent replication experiments. *, 0.01  p < 0.05; **, 0.001  p < 0.01. The p 
values were calculated by using an unpaired two-tailed t-test and referred to comparisons 
with the data obtained for parental AB1157 cells. (c) Higher-resolution “zoom scan” ESI-
MS of the restriction fragments for the PCR products from the replication of Sp-XT-PTEs 
bearing single-stranded M13 genomes in SOS-induced wild-type and the isogenic Ada-
deficient cells. Displayed are the [M-3H]3- ions of the restriction fragments for the bottom 
strand of the replication products of: (A) A(Me)T, (B) C(Me)T, and (C) G(Me)T in AB1157 
cells, respectively, and (D) A(Me)T, (E) C(Me)T and (F) G(Me)T in the isogenic Ada-
deficient cells, respectively. All the mutagenic products were confirmed by MS/MS 
analyses. 
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Primer name Primer Sequence 
ada-Forward Primer 5′- CGGCTCGAGTTACCTCTCCTCATTTTCAGCT -3′ 
ada-Reverse Primer 5′- CGCGGATCCATGAAAAAAGCCACATGCTT -3′ 
Table 3-1. The list of primers used in the present study. 
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 Description Sequence Kd (μM) p value 
a ssAT AGTGGAAGACATGGCATGCTAT 
 
4.28±0.21 
 
2.03×10-4 
b ssA(Me)T-Sp AGTGGAAGACATGGCA(Me)TGCTAT 
 
1.05±0.04 
 
c dsAT AGTGGAAGACATGGCATGCTAT 
TTTTTCACCTTCTGTACCGTACGATATTTT 
2.32±0.09 
 
0.86 
d dsA(Me)T-Sp AGTGGAAGACATGGCA(Me)TGCTAT 
TTTTTCACCTTCTGTACCGT     
ACGATATTTT 
2.35±0.09 
 
e ssTA AGTGGAAGACATGGCTAGCTAT 
 
15.93±1.25 
 
0.26 
f ssT(Me)A-Sp AGTGGAAGACATGGCT(Me)AGCTAT 
 
24.68±0.88 
 
Figure 3-34. Electrophoresis mobility shift assay (EMSA) for quantifying the binding 
capacity of Ada protein with (a) ssAT, (b) ssA(Me)T-Sp, (c) dsAT, (d) dsA(Me)T-Sp, (e) 
ssTA and (f) ssT(Me)A-Sp. The DNA sequences, Kd values and p values are listed in the 
table. 
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CHAPTER 4 
 
Chemical Syntheses and Replication Studies of Pyridyloxobutylphosphotriester 
Lesions in Escherichia coli Cells 
 
INTRODUCTION 
Due to its chemical instability, DNA is susceptible to damage by endogenous and 
exogenous factors, resulting in the formation of various DNA adducts (1,2). If not 
efficiently repaired, these DNA adducts may induce mutations and ultimately result in 
carcinogenesis (3). Tobacco and its combustion products contain more than 8,000 
compounds (4), over 70 of which are classified as carcinogens by the International 
Agency for Research on Cancer (IARC) (5). Among them, two tobacco-specific 
nitrosamines, N′-nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone (NNK), are considered group-I carcinogens (carcinogenic to humans) by the 
IARC (6). Additionally, a reduced metabolite of NNK, 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanol (NNAL) was also revealed to induce cancer in rodents (7-9).  
NNN and NNK can be metabolically activated by cytochrome P450s to form 
reactive intermediates, which could pyridyloxobutylate (POB) DNA to form numerous 
lesions (9-11). Among them, O2-POB-thymidine (O2-POBdT) and O6-POB-2-
deoxyguanosine (O6-POBdG) were detected at significant levels in lung tissues of NNK-
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treated mice, and owing to the lack of N-glycosidic bond stability, O2-POB-cytosine (O2-
POBCyt) and N7-POB-guanine (N7-POBGua) were also detected as nucleobase adducts 
(12). Additionally, some of the POB-modified nucleobase derivatives were found to be 
mutagenic in cells. O6-POBdG could induce G→A mutation in E. coli cells and both 
G→A and G→T mutations in HEK293T cells (13). Du et al. also revealed that, in 
HEK293T cells, O2-POBdT and O4-POBdT could induce T→A and T→C mutations, 
respectively (14). 
Apart from nucleobase adducts, backbone alkylation products, also known as alkyl 
phosphotriesters (alkyl-PTEs) came to our sight in recent years (15). Many alkylating 
agents, e.g. N-methyl-N-nitrosourea, diazomethane and methyl methanesulfonate, could 
attack non-carbon-bonded oxygen atoms at phosphate backbone to form PTEs (16-18). 
Additionally, PTEs constitute approximately 55 % of total alkylated DNA lesions for N-
ethyl-N-nitrosourea (19). Because conjugation with an alkyl group could neutralize the 
negative charge on backbone phosphate, PTEs were shown to perturb the interaction of 
DNA with DNA-binding proteins, including MutS (20), MutY (21) and RNA polymerase 
(22). Results from in vitro primer extension assay revealed that Et-PTE-containing ODN 
could inhibit the replication mediated by purified T4 DNA polymerase and E. coli DNA 
polymerase I (23). Our previous replication study in Escherichia coli cells also unveiled 
that Sp-T(Me)T induced TT→GT and TT→GC mutations, which required the Ada (24). 
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Aside from simple backbone alkylation products, active metabolites of NNN and 
NNK can attack phosphate backbone to form pyridyloxobutylphosphotriesters (POB-
PTEs) (Figure 4-1A). Both NNN and NNK can be activated to form POB-phosphate 
adducts in vitro and in rats (25,26). Similar to other simple alkyl-PTE products, POB-
PTEs are also highly persistent in mammalian tissues. POB-PTEs could remain highly 
abundant in over 70 weeks in lung tissue of rats treated with drinking water containing 5 
ppm NNN (26). Additionally, after chronic exposure to NNK, 55-73% of the total POB 
DNA adducts in rat lung tissues reside on phosphate backbone, suggesting that POB-
PTEs can serve as biomarkers for some tobacco-related diseases, like lung cancer (25). 
However, no research has elucidated how POB-PTEs affect DNA replication in vitro or in 
cells.  
Herein, we synthesized oligodeoxyribonucleotides (ODNs) harboring a site-
specifically incorporated and stereochemically defined POB-PTE lesions, we also 
employed a shuttle vector-based method coupled with LC-MS/MS to assess the impact of 
POB-PTEs at TT dinucleoside site on the efficiency and fidelity of DNA replication in E.  
coli cells. Moreover, we assessed how replication past POB-PTEs is modulated by 
translesion synthesis (TLS) DNA polymerases and Ada protein. 
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EXPERIMENTAL DETAILS 
Chemicals and supplies 
Unless further specified, all chemicals were from Thermo Fisher Scientific (Pittsburg, 
PA, USA). Common reagents for solid-phase ODN synthesis were obtained from Glen 
Research (Sterling, VA, USA). ODNs without modification were purchased from 
Integrated DNA Technologies (Coralville, IA, USA). 1,1,1,3,3,3-Hexafluoro-2-propanol 
(HFIP) was obtained from Oakwood Products Inc. (West Columbia, SC, USA), and [γ-
32P]ATP was purchased from Perkin Elmer (Piscataway, NJ, USA). All enzymes were 
from New England Biolabs (Ipswich, MA, USA). 
   M13mp7(L2) plasmid and wild-type AB1157 E. coli strains were kindly provided 
from Prof. John. M. Essigmann (27,28). Polymerase-deficient AB1157 E. coli strain 
[Δpol B1::spec (Pol II deficient), ΔdinB (Pol IV-deficient), ΔumuC::kan (Pol V deficient) 
and Δpol B1::spec ΔdinB ΔumuC::kan (Pol II, Pol IV, Pol V-triple knockout)] were 
generously provided by Prof. Graham. C. Walker (27). Ada-deficient AB1157 E. coli 
strain was generated following published procedures (28).  
Chemical Synthesis  
The 5′-DMTr-protected thymidine (29) and 4-(1,3-dithian-2-yl)-4-((3-pyridyl) butan-1-ol 
(POB-OH) (30) was synthesized according to published procedures. For dT-
143 
 
phosphoramidite synthesis, compound 2 (100 mg, 0.18 mmol) was dissolved in 3 ml of 
anhydrous CH2Cl2 at room temperature under argon protection. 
Bis(diisopropylamino)chlorophosphine (146 mg, 0.54 mmol) and N,N-
diisopropylethylamine (94 μl, 0.54 mmol) were subsequently added and the reaction 
mixture was stirred for 1 h, followed by vacuum concentration. The residue was isolated 
using column chromatography with a mixture of hexane, ethyl acetate and triethylamine 
(49/49/2, v/v) to obtain compound 3. For the preparation of compound 4, POB-OH (33 
mg, 1.1 eq) was added into a round bottom flask with compound 3 (100 mg, 0.12 mmol), 
followed by addition of 0.25 M 1H-ethylthiotetrazole in acetonitrile (1 eq, Glen 
Research). The reaction mixture was stirred under an argon atmosphere at room 
temperature for 1 h, concentrated by rotary evaporation, and then purified by flash 
column chromatography to obtain compound 4. The synthetic procedures are shown in 
Figure 4-1B. 
ODN synthesis  
A Beckman Oligo 1000M DNA synthesizer (Fullerton, CA) was employed to synthesize 
the 12-mer lesion-containing ODN: 5′-ATGGCT(X)TGCTAT-3′ at 1 μM scale, where ‘X’ 
designates the dithiane-protected POB group. The phosphoramidite building block 
(compound 4) was dissolved in anhydrous acetonitrile at a final concentration of 0.067 
M, and commercially available phosphoramidite building blocks were used for the 
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incorporation of unmodified nucleotides (Glen Research, Sterling, VA, USA) following 
standard protocols. A 55-min treatment with concentrated ammonium hydroxide was 
employed to cleave the synthesized ODNs from controlled pore glass support. After 
solvent removal by Speed-Vac, the solid residue was dissolved in water for HPLC 
purification. 
HPLC  
An Agilent 1100 system with a Thermo Hypersil Gold aQ column (250×4.6 mm, 3 μm in 
particle size and 175 Å in pore size; Thermo Fisher Scientific, Waltham, MA, USA) was 
used for HPLC separation of the synthesized 12-mer ODNs. The mobile phases consisted 
of 50 mM triethylammonium acetate (TEAA, pH 6.8, phase A) and 30% acetonitrile in 
50 mM TEAA (phase B). The gradient profile was 5%-25% B in 5 min, followed by 25-
80% B in 65 min, and the flow rate was 0.5 ml/min. The HPLC trace for the purification 
of the 12-mer lesion-containing ODNs is displayed in Figure 4-2. 
After HPLC purification, the dithiane group on POB was removed by incubation with 
N-chlorosuccinimide (5 eq.) in acetonitrile and water (50:50, v/v, prechilled on ice) at 
room temperature for 10 min. The reaction mixture was purified by HPLC with the 
aforementioned mobile phases and gradient. The electrospray ionization-mass spectra 
(ESI-MS) and tandem MS (MS/MS) for the purified ODNs are provided in Figure 4-3. 
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Construction of single-stranded lesion-containing and lesion-free control M13 
genomes.  
The 12-mer lesion-containing ODNs were 5′-phosphorylated and ligated with a 10-mer 
ODN (5′-AGTGGAAGAC-3′) in the presence of T4 DNA ligase and ATP in the ligase 
buffer (New England Biolabs) at 10 °C for 12 h. The resulting 22-mer ligation product 
was purified by denaturing polyacrylamide gel electrophoresis (PAGE). 
The lesion-containing and lesion-free single-stranded M13mp7 plasmids were 
prepared following previously published procedures (27). Briefly, 20 pmol of M13 vector 
was linearized by digestion using 40 U EcoRI-HF at 25 °C for 8 h. Two scaffolds were 
used for the ligation, 5′-CTTCCACTCACTGAA TCATGGTCATAGCTTTC-3′ and 5′-
AAAACGACGGCCAGTGAATTATAGC-3′ (25 pmol), each of which spanned one end 
of the linearized vector. The above-described 5′-phosphorylated 22-mer lesion-containing 
or 25-mer competitor ODNs were subsequently ligated to M13 plasmid and incubated 
with T4 DNA ligase at 16 °C for 8 h. Excess ODNs and unligated vector were cleaved by 
the exonuclease activity of T4 polymerase (22.5 U) at 16 °C for 2 h. Cycle Pure Kit 
(Omega) was employed to purify the lesion-containing or lesion-free vectors. 
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Transfection of M13 plasmids into E. coli cells  
The lesion-containing and lesion-free control vectors were mixed individually with the 
competitor vector at a 1:1 molar ratio. The mixtures were then transfected into wild-type 
(WT) AB1157 E. coli strains, or the isogenic strains deficient in Pol II, Pol IV, Pol V, or 
all three in combination (TKO), or Ada. The transfected E. coli cells were cultured at 
37 °C for 5.5 h, and the M13 phage was recovered from the supernatant by centrifugation 
at 13,200 rpm for 5 min and then transfected to SCS110 E. coli strain for amplification, 
and the M13 phages were extracted by using QIAprep Spin M13 Kit (Qiagen).  
Quantification of bypass efficiency by competitive replication and adduct bypass 
(CRAB) assay  
A modified version of the competitive replication and adduct bypass (CRAB) assay was 
employed to quantify the bypass efficiencies of POB-PTE lesions in E. coli cells 
(27,29,31,32). The regions of the replication products harboring the lesion-containing site 
were amplified by PCR with the use of Phusion high-fidelity DNA polymerase, with the 
primers being 5′-YCAGCTATGACCATGATTCAGTGAGTGGA-3′ and 5′-
YTCGGTGCGGGCCTCTTCGCTATTAC-3′, where ‘Y’ denotes the H2N(CH2)6- group 
being conjugated to the 5′-phosphate group of the ODNs. The PCR amplification began 
from 98 °C for 30 s, followed by 35 cycles of amplification, with each cycle consisting 
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98 °C for 10 s, 65 °C for 30 s and 72 °C for 15 s, and then with a final extension at 72 °C 
for 5 min, ending at 4 °C. The PCR products were purified by Cycle Pure Kit (Omega). 
PCR products (100 ng) were digested with BbsI-HF restriction endonuclease (5 U) 
and recombinant shrimp alkaline phosphatase (rSAP, 10 U) in a 10 μl CutSmart buffer 
(New England Biolabs) at 37 °C for 30 min, followed by deactivation at 70 °C for 10 
min. To the mixture were subsequently added 10 U T4 polynucleotide kinase (T4 PNK), 
5 mM dithiothreitol (DTT), 1.66 pmol [γ-32P]ATP, NEB CutSmart buffer, and water to a 
total volume of 15 μl. The reaction was continued at 37 °C for 30 min, and T4 PNK was 
deactivated by heating the solution at 70 °C for 10 min. Next, 10 U MluCI was added to 
the above mixture, which was incubated at 37 °C for 25 min. The digestion reaction was 
terminated by adding 15 μl formamide gel-loading buffer containing xylene cyanol FF 
and bromophenol blue. The aforementioned digestion yielded 10 mer radiolabeled 
fragments for lesion-containing or control genome (5′-GGCMNGCTAT-3′, ‘M’ and ‘N’ 
being nucleobases at the dinucleotides initially flanking the lesion site), and a 13 mer 
fragment for competitor genome (5′-GGCGATAAGCTAT-3′), which were resolved using 
30% native polyacrylamide gel (19:1). The intensities for the radiolabeled bands were 
quantified by using a Typhoon 0410 imager, and the bypass efficiency was calculated by 
using the following equation: Bypass efficiency (%) = (lesion signal/competitor 
signal)/(control signal/competitor signal) × 100%. 
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Identification of replication products by mass spectrometry  
Approximately 3 μg of PCR products were digested by 50 U BbsI-HF and 20 U rSAP in 
250 μl CutSmart buffer at 37 °C for 2 h, followed by deactivation at 70 °C for 20 min. To 
the above mixture was subsequently added 20 U MluCI, and the digestion was continued 
at 37 °C for 1 h. The solution was extracted once with phenol/ chloroform/isoamyl 
alcohol (25:24:1 v/v) and the aqueous layer was collected and concentrated. The resulting 
solid residue was dissolved in 100 μl water and desalted using Waters Oasis HLB 
extraction cartridge (Milford, MA). The eluate was evaporated by Speed-Vac, redissolved 
in 10 μl water and subjected to LC-MS and MS/MS analyses. An LTQ linear ion trap 
mass spectrometer (Thermo Electron, San Jose, CA, USA) with an Agilent 1200 capillary 
HPLC pump was used to analyze the digestion products and a Zorbax SB-C18 column 
(0.5 × 150 mm, 5 μm in particle size) was employed for the separation. Mobile phases A 
and B contained 400 mM HFIP (pH 7.0) and methanol, respectively. The gradient was 5-
20% B in 5 min and 20-50% B in 35 min. The ion-transfer tube temperature was 275 °C 
and the mass spectrometer was set up for recording the higher-resolution ultra-zoom scan 
MS and MS/MS for the cleavages of [M-3H]3- ions for 10 mer d(GGCMNGCTAT), with 
‘N’ and ‘M’ being A, T, C and G. 
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RESULTS 
The objectives of this study were to assess the impact of POB-PTEs on DNA replication, 
to define the roles of three translesion synthesis (TLS) polymerases in bypassing these 
lesions, and to examine the function of Ada in modulating the replication across the POB-
PTEs in E. coli cells. 
  We synthesized and characterized 12-mer ODNs containing a site-specifically inserted 
POB-PTE lesion. The synthesized ODNs were purified by HPLC and characterized with 
ESI-MS and MS/MS. Our previous results revealed that using C18 reverse phase column 
with TEAA/acetonitrile as mobile phases, the Sp diastereomer of alkyl-PTEs eluted 
earlier than the corresponding Rp diastereomer (24). Here, we assign the earlier- and later-
eluting fractions as the Sp- and Rp-POB-PTE-harboring ODNs, respectively. The MS/MS 
results confirmed the sequence of the synthesized ODNs and verified the location of POB 
group conjugated with the phosphate backbone (Figure 4-3).  
   We employed a shuttle-vector method to assess the bypass efficiencies of the POB-
PTEs lesions (27). The mixture of lesion-containing and competitor vectors was 
transfected into AB1157 E. coli strains proficient or deficient with SOS-induced DNA 
polymerases. After replication, the progeny was extracted, followed by PCR 
amplification. The PCR products were subsequently digested with two restriction 
endonucleases, BbsI and MluCI, yielding10 mer ODNs, which contain the replication 
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products of initial damage-containing site, for lesion-containing or lesion-free control 
genome, or 13 mer for the corresponding region of the competitor genome, of which the 
5′-terminius was radiolabeled (Figure 4-4). By switching the order of digestion for the 
two restriction enzymes, either the lesion-situated strand (p*GGCMNGCTAT) or the 
corresponding complementary strand (p*AATTATAGCY) can be radiolabeled (see 
Experimental Procedures). The resulting ODNs were analyzed by native PAGE and LC-
MS/MS. 
   Alkylation of the phosphate backbone can potentially influence the fidelity of 
replication of both nucleosides flanking the PTE site (24), yielding up to 16 replication 
products (A, T, C or G being incorporated at the flanking nucleoside sites), which cannot 
be completely resolved by PAGE. Therefore, we subjected the aforementioned digestion 
products to LC-MS and MS/MS analyses, where we monitored the [M-3H]3- ions of 
d(GGCMNGCTAT). The LC-MS/MS data showed that neither Sp- nor Rp-POB-PTEs was 
mutagenic, which is agreement with the PAGE analysis results (Figure 4-6, 4-7). 
   After identification of replication products, the bypass efficiencies of POB-PTEs were 
determined by comparing the intensity ratio of 10-mer band from the lesion-containing 
genome over the corresponding 13-mer bands from the competitor genome (Figure 4-5). 
The results showed that neither Sp- nor Rp-POB-PTE was strong impediment to DNA 
replication. Additionally, we assessed the role of three SOS-induced translesion synthesis 
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polymerases (Pol II, Pol IV and Pol V) in bypassing the POB-PTEs by conducting the 
CRAB assay using isogenic E. coli strains deficient in Pol II, Pol IV, Pol V, or all three in 
combination. The result showed that the replicative bypass of POB-PTEs did not require 
any of the SOS-induced DNA polymerases.  
   Previous research has found that E. coli Ada protein could remove Sp-Me-PTE, and is 
required for the mutagenic bypass of the Sp-Me-PTE at TT site (24,33). We next asked if 
Ada protein can influence the bypass efficiency or mutation patterns of the bulky POB-
PTEs, and we observed that depletion of Ada protein could not affect the replication 
efficiencies or induce mutations of the POB-PTEs (Figure 4-5). 
DISCUSSION 
In the present study, we assessed how POB-PTEs flanked by TT influence DNA 
replication. First, we revealed that neither Sp- nor Rp-POB-PTEs showed significant 
blockage effect, which is, to some extent, similar to what we found for nBu-PTEs in same 
sequence context (24). Sp-POB-PTE did not display significant difference in bypass 
efficiency compared with nBu-PTE, whereas Rp-POB-PTEs exhibited an elevated bypass 
efficiency relative to Rp-nBu-PTEs. Tsujikawa et al. (23) indicated that Rp-Et-PTE at TT 
sequence could cause bending of the template strand, which may introduce dynamic 
change to DNA-polymerase interactions, resulting in stronger steric hinderance and lower 
bypass efficiency of Rp-Et-PTE than the Sp counterpart (24). However, our results 
152 
 
indicated that this distinction in bypass efficiency for the two diastereomers of PTEs were 
narrowed with the increasing size of alkyl group conjugated with the backbone 
phosphate, suggesting that some other factors may modulate the aforementioned 
distortion-induced steric hindrance. 
Second, we observed that the bypass efficiencies and mutagenic properties of POB-
PTEs were not impacted by genetic depletion of the three SOS-induced DNA 
polymerases (Pol II, Pol IV and Pol V), alone or all three together, which is consistent 
with what we observed for simple alkyl-PTEs with different size of alkyl group and 
stereochemistry, as well as flanking base sequences around PTE site (24), supporting 
replication across these lesions does not require these TLS polymerases.  
Previous research has revealed that E. coli Ada protein can remove Sp-Me-PTE, albeit 
at the expense of eliciting mutations (24,33). Here we found no apparent change in the 
efficiencies or fidelity of replication across POB-PTEs introduced by depletion of Ada, 
suggesting the lack of interaction between Ada and POB-PTEs.  
In summary, the results from our shuttle vector-based replication study showed that 
POB-PTEs did not impede DNA replication or introduce mutations during DNA 
replication. Meanwhile, genetic depletion of TLS polymerases does not impact the 
replication bypass efficiencies of POB-PTEs, and Ada is incapable of removing POB 
phosphate adducts. Our study provided, for the first time, the knowledge about how bulky 
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POB group on phosphate backbone influences DNA replication in vivo. Future studies 
about how POB-PTEs affect DNA replication and transcription in mammalian cells will 
offer additional insights into the biological impacts of this unique class of DNA damage.  
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FIGURES AND SCHEMES 
 
Figure 4-1. (A) The structures of the Sp and Rp diastereomers of POB-PTEs at TT site. (b) 
Chemical Synthesis of the POB the phosphoramidite building block. Reagents and 
conditions: (B) 4,4′-dimethoxytrityl chloride, 4-dimethylaminopyridine, pyridine, R. T., 10 
h; (b) bis(diisopropylamino)chlorophosphine, N,N-diisopropylethylamine, 
dichloromethane, R. T. 1 h, (c) 4-(1,3-dithian-2-yl)-4-((3-pyridyl) butanol, 
ethylthiotetrazole, acetonitrile, dichloromethane, R. T. 1 h. 
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Figure 4-2. HPLC trace for the separation of the synthesized 12 mer dithiane-protected 
POB-PTE-bearing ODNs. 
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Figure 4-3. ESI-MS & MS/MS characterizations of d(ATGGCT(POBSp)TGCTAT): 
Negative-ion ESI-MS (top) and the product-ion spectrum of the [M-3H]3- ion (m/z 1265.2) 
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Figure 4-4. Restriction enzyme digestion and radiolabeling, followed by native PAGE 
(30%) analysis for quantifying the bypass efficiencies of POB-PTE lesions located at TT 
dinucleotide site in AB1157 E. coli cells. (a) Selective labelling of the original lesion-
containing strand and its complementary strand via sequential restriction digestion. ‘SAP’ 
and ‘PNK’ designate shrimp alkaline phosphatase and T4 polynucleotide kinase, 
respectively. ‘MN’ indicate the flanking nucleobases of the site where the POB-PTE lesions 
was initially situated. (b) Gel image showing the 13 mer (competitor genome) and 10 mer 
(control or lesion-containing genome) digestion products formed from the original strand, 
where 10 mer TT designates [5-32P]-labeled standard ODNs 5-GGCMNGCTAT-3, with 
MN being TT, respectively.  
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Figure 4-5. Bypass efficiencies of POB-PTEs in AB1157 E. coli strains that are proficient 
in translesion synthesis and Ada, or with Ada protein or three SOS-induced DNA 
polymerases (Pol II, Pol IV and Pol V) being genetically depleted alone or in combination. 
The data represent the mean and standard deviation of results from three independent 
replication experiments.  
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Figure 4-6. Higher-resolution “ultrazoom scan” ESI-MS of the restriction fragments for 
the PCR products from the replication of single-stranded M13 genomes harboring a site-
specifically inserted (a) Sp-T(POB)T and (b) Rp-T(POB)T in AB1157 cells. Displayed in 
(a) and (b) are the [M-3H]3- ions of the strand initially contained the lesion.  
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Figure 4-7. MS/MS for the identification of restriction fragments of PCR products. 
MS/MS for the [M-3H]3- ions of 10mer TT sequence from replication product of Sp-POB-
PTE-containing genome. 
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CHAPTER 5 
 
Concluding Remarks and Future Directions 
 
     In this dissertation, we investigated how differences in sizes, structures, 
stereochemical configuration and sequences contexts of alkyl phosphotriesters (alkyl-PTEs) 
influence the efficiency and fidelity of DNA replication by using the competitive 
replicative adduct bypass (CRAB) assay. We also examined how translesion synthesis 
(TLS) polymerases modulate the replicative bypass of alkyl-PTEs in E. coli cells. 
Additionally, since E. coli Ada protein has been found to remove Sp-Me-PTEs, we also 
characterized the cytotoxicity and mutagenicity of Sp-Me-PTEs induced by Ada protein 
and analyzed the sequence-dependent interaction of Ada protein with Sp-Me-PTEs.  
In Chapter 2, we synthesized oligodeoxyribonucleotides (ODNs) containing alkyl-
PTEs (with the four alkyl groups being Me, Et, nPr or nBu) at TT site, followed by 
separation and identification of the two diastereomers by using HPLC and NMR analysis. 
We also conducted replication studies in E. coli cells, and our results showed that the Sp 
diastereomers of alkyl-PTEs could be efficiently bypassed, whereas their Rp counterparts 
exhibited moderate blockage effects. Additionally, Sp-Me-PTEs induced TT→GT and 
TT→GC mutations, which depend on the Ada protein. Moreover, genetic depletion of 
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polymerase II, IV and V, alone or all three in conjunction, conferred subtle changes on 
bypass efficiencies and mutation frequencies of the alkyl-PTEs in E. coli. Taken together, 
these results provided a comprehensive understanding about the recognition of alkyl-PTE 
lesions by DNA replication machinery in E. coli cells and revealed for the first time the 
Ada-dependent induction of mutations at Sp-Me-PTE site. 
In Chapter 3, we investigated the impact of flanking base sequences on the replication 
across alkyl-PTE lesions. We prepared ODNs with Me- and nBu-PTEs in different flanking 
base sequences (XT and TX, with X being A, C and G) and assessed how these lesions 
perturb DNA replication in E. coli cells. Our results indicated that Sp-XT-Me-PTEs were 
not strong impediments to DNA replication. Moreover, their replication products were 
highly sequence-independent, which comprise 85-90% AT and 5-10% TG. Ada protein was 
again critical for the formation of these mutagenic products. The Rp diastereomers, however, 
exhibited error-free bypass with strong blockage effect. Unlike what we found for XT-Me-
PTEs, TX-Me-PTEs were not mutagenic, and elicited moderate blockage effects on DNA 
replication. Additionally, none of Sp-XT-nBu-PTEs significantly impeded DNA replication, 
whereas Rp- XT-nBu-PTEs and all TX-nBu-PTEs moderately blocked replication, with 
none of the nBu-PTEs being mutagenic. Consistent with what we found for T(alkyl)T, 
depletion of all three TLS polymerases did not exert apparent effects on replicative bypass 
of Me-PTEs in different sequence contexts.  
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The differences in Ada-induced mutagenicity between XT- and TX-Sp-Me-PTEs 
suggested that Ada’s interaction with PTE site was also sequence-dependent. We prepared 
22-mer Sp-Me-PTE with flanking base sequences being AT or TA and employed 
electrophoresis mobility shift assay (EMSA) to analyze their binding capacities to Ada 
protein, and we found that Sp-A(Me)T bound strongly to Ada protein relative to that of Sp-
T(Me)A. In summary, our study provides further understanding about how alkyl-PTE 
lesions are recognized by DNA replication machinery in prokaryotic cells, and our results 
suggest that the role of Ada may be beyond the repair of Sp-Me-PTE lesion and 
transcriptional modulation of genes involved in repairing alkylated DNA lesions. 
In chapter 4, we assessed how POB-PTEs modulated the efficiency and fidelity of 
DNA replication and how their replicative bypass is mediated by TLS polymerases and 
Ada protein. Our replication studies showed that neither Sp- nor Rp-POB-PTEs elicited 
significant impediment to DNA replication in E. coli. We also examined the roles of 
translesion synthesis polymerases in bypassing POB-PTEs by conducting the replication 
assay in isogenic E. coli strains with SOS-induced DNA polymerases being depleted 
individually and together, and the results indicated that the replicative bypass of POB-PTEs 
did not require TLS polymerases. LC-MS/MS results also showed that POB-PTEs were 
not mutagenic. Therefore, our data provided a comprehensive understanding about how 
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tobacco-specific nitrosamine-induced POB-PTE adducts are recognized by the entire E. 
coli DNA replication machinery. 
Further studies can be conducted, and they can focus on the following aspects: 1) It 
remains elusive how alkyl-PTEs influence replication and transcription in mammalian cells. 
Ma et al. (1) detected alkyl-PTEs in lung tissue of lung cancer patients, and an increased 
level of Me-PTEs was observed in lung tissues of smokers compared with that of non-
smokers. In this dissertation, we mainly focus on the cytotoxic and mutagenic effects of 
alkyl-PTEs in E. coli cells, whereas the replication, repair and transcription machinery in 
mammalian cells are more complicated and distinct. For instance, E. coli Ada protein do 
not have mammalian homologues. Thus, it will be important to further extend our 
replication study to mammalian cells. 2) Phosphate adducts were found not only being 
lesions, but also being endogenous modifications. Many studies have detected and 
sequenced endogenous phosphorothioation in bacterial genomes and suggested its function 
in a restriction-modification system (2). It will be of interest to investigate whether 
endogenous alkyl-PTEs can be detected, if so, how backbone alkylation products 
contribute to gene regulation in E. coli cells.  
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